02-07-2025 | Medexus Pharmaceuticals Inc. | TSX: MDP | Good FY3Q-2025 Results (Previously Announced). Terbinafine not Approved. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-23-2025 | Medexus Pharmaceuticals Inc. | TSX: MDP | Treosulfan Approval Boosts Outlook | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-22-2025 | ESSA Pharma Inc. | NASDAQ: EPIX | Discontinuing Coverage | Biotechnology | Download | biotechnology |
01-10-2025 | Repare Therapeutics Inc. | NASDAQ: RPTX | Lunresertib + Camonsertib Pivotal Program De-Prioritized to Focus on Earlier Clinical Assets. | Biotechnology | Download | biotechnology |
12-20-2024 | Microbix Biosystems Inc. | TSX: MBX | FY4Q-2024 Strong. Green Shoots. | Medical Technology | Download | medical-technology |
12-16-2024 | Top Ideas | | 2025 Top Ideas | Biotechnology, Healthcare Services | Download | biotechnology healthcare-services |
12-13-2024 | Repare Therapeutics Inc. | NASDAQ: RPTX | Positive Phase 2 Expansion Data in Tough Patients – Supports Phase 3 Development in Genomically-Defined Patient Population Currently with no Good Options. | Biotechnology | Download | biotechnology |
12-11-2024 | DRI Healthcare Trust. | TSX: DHT-U; TSX: DHT/U | Mixed Phase 3 Results for Lilly’s Imlunestrant – No Changes to our DRI Orserdu Estimates. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-05-2024 | Medicenna Therapeutics Corp. | TSX: MDNA | One Extra Month Adds a Combo CR. | Biotechnology | Download | biotechnology |
12-02-2024 | Hamilton Thorne Ltd. | TSX: HTL | Discontinuing Coverage | Healthcare Services | Download | healthcare-services |
11-21-2024 | Zymeworks Inc. | NASDAQ: ZYME | First Approval for Zanidatamab (Ziihera). | Biotechnology | Download | biotechnology |
11-21-2024 | BioSyent Inc. | TSX-V: RX | 3Q-2024 Results: Core Performing Well. Beat on Legacy and International Business. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-19-2024 | Cybin Inc. | NYSE American: CYBN; CBOE: CYBN | CYB003 Benefit Durable at 12 Months. | Biotechnology | Download | biotechnology |
11-11-2024 | CareRx Corp. | TSX: CRRX | 3Q-2024 Results: Margins Rising/Debt Decreasing – Will Be Fuel For When New Beds Finally Hit | Healthcare Services | Download | healthcare-services |
11-10-2024 | Medexus Pharmaceuticals Inc. | TSX: MDP | FY2Q-2025 Results: Rupall’s Last Solo Season Keeps the Canadian Portfolio Performing. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-10-2024 | Medicenna Therapeutics Corp. | TSX: MDNA | SITC Download – 1 More Melanoma Mono PR – ORR Dips on NMSC. 1 Combo PR in Tough Patients – Early but Promising. MDNA11 Remains Best in Class. | Biotechnology | Download | biotechnology |
11-10-2024 | Aurinia Pharmaceuticals Inc. | NASDAQ: AUPH | 3Q-2024 Results: EBITDA Beat on Aggressive Cost Cutting – More to Come | Biotechnology | Download | biotechnology |
11-08-2024 | Knight Therapeutics Inc. | TSX: GUD | 3Q-2024 Results Mixed. Mid-term Outlook Strengthening. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-08-2024 | DRI Healthcare Trust. | TSX: DHT-U; TSX: DHT/U | 3Q-2024 Results: Two Steps Forward with No Looking Back. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-08-2024 | HLS Therapeutics Inc. | TSX: HLS | 3Q-2024 Results: U.S Clozaril Dip (Expect Temporary); Vascepa Not Missing Pfizer. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-05-2024 | AbCellera Biologics Inc. | NASDAQ:ABCL | 3Q-2024 Financial Results. Growing Pains. | Biotechnology | Download | biotechnology |
11-05-2024 | DRI Healthcare Trust. | TSX:DHT-U; TSX:DHT/U | New Deal HAErmonizes With Our Model. | | Download | |
11-01-2024 | ESSA Pharma Inc. | NASDAQ: EPIX | End of the line for Masofaniten | Biotechnology | Download | biotechnology |
11-01-2024 | Cybin Inc. | NYSE American: CYBN; CBOE: CYBN | Compass Turns South, No Change in our View of Cybin’s Direction. | Biotechnology | Download | biotechnology |
10-07-2024 | DRI Healthcare Trust. | TSX:DHT-U; TSX:DHT/U | Editing in Confidence with Casgevy Deal | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-25-2024 | Aurinia Pharmaceuticals Inc. | NASDAQ: AUPH | Lupkynis Approved in Japan. Incremental Revenues Expected…but, a M&A Catalyst? | Biotechnology | Download | biotechnology |
09-23-2024 | BioSyent Inc. | TSX-V:RX | Tibella Global Rights Acquired – A Low Risk Growth Play Highlights | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-12-2024 | Repare Therapeutics Inc. | NASDAQ: RPTX | Precision BUY. | Biotechnology | Download | biotechnology |
08-27-2024 | BioSyent Inc. | TSX-V: RX | 2Q-2024 Results In Line. Steady as She Goes: Revenue Growth, Buybacks, and Dividends. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-15-2024 | Microbix Biosystems Inc. | TSX: MBX | FY3Q-2024 Results: Priming the Pump. | Medical Technology | Download | medical-technology |
08-12-2024 | Cybin Inc. | NYSE American: CYBN | Lykos Setback Likely Positive for Cybin Long Term. | Biotechnology | Download | biotechnology |
08-09-2024 | Medexus Pharmaceuticals Inc. | TSX: MDP | FY1Q-2025 Results Mixed: Treosulfan FDA Approval Key to Upside (decision October 30). | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-09-2024 | HLS Therapeutics Inc. | TSX: HLS | 2Q-2024 Results In Line (no unexpected bumps!) | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-09-2024 | Knight Therapeutics Inc. | TSX: GUD | 2Q-2024 Results: Raising Target | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-08-2024 | AbCellera Biologics Inc. | NASDAQ:ABCL | Soft 2Q-2024 Results Reflect Focus Shift. Invetx Monetization a Sign of Percolating Value. | Biotechnology | Download | biotechnology |
08-08-2024 | DRI Healthcare Trust. | TSX:DHT-U; TSX:DHT/U | 2Q-2024 Results In Line. Moving On. Sufficient Dry Powder. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-02-2024 | Aurinia Pharmaceuticals Inc. | NASDAQ: AUPH | Mixed 2Q-2024 Results | Biotechnology | Download | biotechnology |
07-03-2024 | HLS Therapeutics Inc. | TSX:HLS | Small (First?) Step to Unlock Value | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-03-2024 | DRI Healthcare Trust. | TSX:DHT-U; TSX:DHT/U | Doubling Down on Xenpozyme | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-27-2024 | Repare Therapeutics Inc. | NASDAQ: RPTX | Early Minotaur Results Moderately Encouraging. | Biotechnology | Download | biotechnology |
06-27-2024 | Medexus Pharmaceuticals Inc. | TSX: MDP | FY4Q-2024 Results: Stalled Growth Awaits the Treosulfan Lifeline. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-06-2024 | Fusion Pharmaceuticals Inc. | NASDAQ: FUSN | Discontinuing Coverage | Biotechnology | Download | biotechnology |
06-05-2024 | Cybin Inc. | NYSE American:CYBN | Lykos Not Liked by FDA Ad Comm – Issues Seem Specific to Lykos, and Cybin Can Potentially Benefit from Lykos’ Stumble. | Biotechnology | Download | biotechnology |
05-21-2024 | BioSyent Inc. | TSX-V: RX | 1Q-2024 Revenues in Line; Margins Ahead. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-16-2024 | Microbix Biosystems Inc. | TSX: MBX | Strong FY2Q-2024 Results. Outlook In-Tact Despite Partner’s Stumble. | Medical Technology | Download | medical-technology |
05-15-2024 | Hamilton Thorne Ltd. | TSX: HTL | 1Q-2024 Results: Revenues Grew 16%; EBITDA 24% – Operating Leverage May be Kicking In. | Healthcare Services | Download | healthcare-services |
05-13-2024 | CareRx Corp. | TSX: CRRX | 1Q-2024 Results: Stage Set for Second Half Spark. | Healthcare Services | Download | healthcare-services |
05-10-2024 | Knight Therapeutics Inc. | TSX: GUD | 1Q-2024 Results: The Jorney Begins (with a Beat). | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-10-2024 | HLS Therapeutics Inc. | TSX: HLS | 1Q-2024 Financial Results. Storm Before the Calm? | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-09-2024 | AbCellera Biologics Inc. | NASDAQ: ABCL | 1Q-2024 Financials as Expected. Long Term Potential Remains Broad But With Visible Catalysts Still a Way Off. | Biotechnology | Download | biotechnology |
05-08-2024 | DRI Healthcare Trust | TSX: DHT-U; TSX: DHT/U | 1Q-2024 Results: 2 Steps Forward; 1 Step Back | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-03-2024 | Aurinia Pharmaceuticals Inc. | NASDAQ: AUPH | 1Q-2024 Results: More Patients and Higher Pricing – Most Cylinders Firing. | Biotechnology | Download | biotechnology |
05-03-2024 | Cybin Inc. | NYSE American: CYBN, CBOE: CYBN | Initiating Coverage with BUY (Speculative); TP US$3.00. Leading Innovative Psychedelic. | Biotechnology | Download | biotechnology |
04-19-2024 | Repare Therapeutics Inc. | NASDAQ: RPTX | Roche is Gone, But ATRi Still Very Much Alive; RPTX is Trading at Half of Proforma Cash. Broad Pipeline with Multiple 2024 Data Points. Reinstating BUY. | Biotechnology | Download | biotechnology |
04-10-2024 | Medicenna Therapeutics Corp. | TSX: MDNA | MDNA11 vs STK-012 – We Give the Edge to MDNA11. | Biotechnology | Download | biotechnology |
03-28-2024 | Hamilton Thorne Ltd. | TSX:HTL | 4Q-2023 Results: Mixed With Encouraging Signs | Healthcare Services | Download | healthcare-services |
03-22-2024 | Knight Therapeutics Inc. | TSX: GUD | 4Q-2023 Results: Short Term Pain Before Long Term Gain. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-20-2024 | Fusion Pharmaceuticals Inc. | NASDAQ: FUSN | AstraZeneca Fuses with Fusion | Biotechnology | Download | biotechnology |
03-15-2024 | HLS Therapeutics Inc. | TSX:HLS | 4Q-2023 Financial Results. On The Right Path. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-15-2024 | BioSyent Inc. | TSX-V:RX | 4Q-2023 Results: Marketing Investments Lead New Product Traction. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-12-2024 | Zymeworks Inc. | NASDAQ:ZYME | NDR Download. Model Update. | Biotechnology | Download | biotechnology |
03-11-2024 | Medexus Pharmaceuticals Inc. | TSX:MDP | Overview of Major Commercial and Pipeline Products – Upside Hinges on Treosulfan. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-08-2024 | CareRx Corp. | TSX: CRRX | 4Q-2023 Results: Healthy Dose of Efficiency, but Beds in Hibernation Until 2H-2024. | Healthcare Services | Download | healthcare-services |
03-01-2024 | DRI Healthcare Trust. | TSX:DHT-U; TSX:DHT/U | 4Q-2023 Results: Orserdu Does it. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-28-2024 | Greenbrook TMS Inc. | OTC: GBNHF | Discontinuing Coverage | Healthcare Services | Download | healthcare-services |
02-22-2024 | AbCellera Biologics Inc. | NASDAQ:ABCL | 4Q-2023 In Line. Model Adjustments Continue as Strategy Evolves. Internal Pipeline Coming into Focus, But not yet in Our Valuation. Investors with Long Focus Should be Rewarded. | Biotechnology | Download | biotechnology |
02-16-2024 | Aurinia Pharmaceuticals Inc. | NASDAQ: AUPH | 4Q-2023 Results: No Acquisitive Love for AUPH This Valentine’s. | Biotechnology | Download | biotechnology |
02-15-2024 | Microbix Biosystems Inc. | TSX:MBX | FY1Q-2024: Revenue Growth Drivers Driving. EBITDA Miss on Higher OpEx (Some One Time). | Medical Technology | Download | medical-technology |
02-13-2024 | Repare Therapeutics Inc. | NASDAQ: RPTX | Roche Terminates Camonsertib Collaboration. | Biotechnology | Download | biotechnology |
02-09-2024 | Medexus Pharmaceuticals Inc. | TSX:MDP | Weak FY3Q-24 on IXINITY Concerns. All Eyes on Treosulfan as Future Growth Driver. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-02-2024 | DRI Healthcare Trust. | TSX:DHT-U; TSX:DHT/U | Oh My – Omidria Royalty Gets Bigger, and so Does Short- and Long-Term Guidance | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-22-2024 | Knight Therapeutics Inc. | TSX: GUD | Pipeline Dive Confirms Thesis | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-05-2024 | Fusion Pharmaceuticals Inc. | NASDAQ:FUSN | Encouraging (Still Early) FPI-1434 Results. Plotting the Path for FPI-2265 | Biotechnology | Download | biotechnology |
01-04-2024 | Microbix Biosystems Inc. | TSX:MBX | 4Q-2023 Results Miss, But Outlook Improving | Medical Technology | Download | medical-technology |
12-22-2023 | Top Ideas | | 2024 Top Ideas | Sector Reports | Download | sector-reports |
11-28-2023 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | X-NOVA Results – Concept Proven, Expanding Potential for XEN1101. Multiple Go-Forward Options. | Biotechnology | Download | biotechnology |
11-20-2023 | Repare Therapeutics Inc. | NASDAQ:RPTX | Two Programs Added to Pipeline – Early but With Promise. | Biotechnology | Download | biotechnology |
11-17-2023 | BioSyent Inc. | TSX-V: RX | 3Q-2023 Results: Lumpy Beat. Pipeline Coming into Focus. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-16-2023 | DRI Healthcare Trust | TSX: DHT-U; TSX: DHT/U | 3Q-2023 Results: Firing on all Cylinders. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-14-2023 | Hamilton Thorne Ltd. | TSX-V:HTL | 3Q-2023 Results: Strong Americas Offset by Consumable Recall and China Softness. | Healthcare Services | Download | healthcare-services |
11-13-2023 | Knight Therapeutics Inc. | TSX: GUD | 3Q-2023. Portfolio Advances Blunt Generics Which have been Slower to Launch. Increasing TP. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-10-2023 | Medexus Pharmaceuticals Inc. | TSX: MDP | 2Q-2024 Results Mixed. Pipeline Has Realistic Near-Term Upside | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-10-2023 | HLS Therapeutics Inc. | TSX:HLS | 3Q-2023 Results. Unexpected Royalty Hit. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-10-2023 | Greenbrook TMS Inc. | NASDAQ:GBNH | 3Q-2023 Results. Turning a Corner, But is it Fast Enough? | Healthcare Services | Download | healthcare-services |
11-09-2023 | Xenon Pharmaceuticals Inc. | NASDAQ: XENE | Partner, Neurocrine, Fails with NBI-921352 in Phase 2b. | Biotechnology | Download | biotechnology |
11-09-2023 | CareRx Corp. | TSX: CRRX | 3Q-2023 Results in Line. | Healthcare Services | Download | healthcare-services |
11-06-2023 | Medicenna Therapeutics Corp. | TSX: MDNA | Hitting the Sweet Spot Just in Time for Dose Expansion. | Biotechnology | Download | biotechnology |
11-03-2023 | AbCellera Biologics Inc. | NASDAQ:ABCL; | 3Q-2023. Seeing a Bit More of the Iceberg. | Biotechnology | Download | biotechnology |
11-03-2023 | Aurinia Pharmaceuticals Inc | NASDAQ:AUPH | Summer Heat Can’t Stop a Summer Beat | Biotechnology | Download | biotechnology |
10-23-2023 | ESSA Pharma Inc. | NASDAQ:EPIX | Overall Phase 1/2 Continues to Support Benefit of Masofaniten. Cohort 4 not yet Mature. Key Phase 2 Trial Recently Initiated. | Biotechnology | Download | biotechnology |
10-17-2023 | DRI Healthcare Trust | TSX:DHT-U; TSX:DHT/U | Low Risk Play on Biopharma Innovation. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-16-2023 | Repare Therapeutics Inc. | NASDAQ:RPTX | Anemia Not Likely a Big Problem so Sell-off Likely a Buying Opportunity. Narrowing in on Select Indications. | Biotechnology | Download | biotechnology |
10-11-2023 | Hamilton Thorne Ltd. | TSX-V:HTL | Gynetics Acquisition Adds 7% to Revenues (all Recurring); Accelerates Margin Expansion and has Synergy Potential | Healthcare Services | Download | healthcare-services |
09-26-2023 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Gearing Up for the Upcoming MDD Readout | Biotechnology | Download | biotechnology |
09-15-2023 | Liminal BioSciences Inc. | NASDAQ:LMNL | Discontinuing Coverage. | Biotechnology | Download | biotechnology |
08-23-2023 | BioSyent Inc. | TSX-V:RX | 2Q-2023 Results: Strong Top Line but Product Launch Activities Weigh on Profitability | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-18-2023 | Hamilton Thorne Ltd. | TSX-V:HTL | 2Q-2023 Results. Single Digit 2024E EV/EBITDA a Buying Opportunity. | Healthcare Services | Download | healthcare-services |
08-16-2023 | Greenbrook TMS Inc. | NASDAQ:GBNH | 2Q-2023 Results: Good but Not Perfect. | Healthcare Services | Download | healthcare-services |
08-15-2023 | Microbix Biosystems Inc. | TSX:MBX | 3Q-2023 Results: Weak Margins Impacted by a DxTM Write-Down and Product Mix | Medical Technology | Download | medical-technology |
08-11-2023 | Chinook Therapeutics Inc., Bellus Health Inc. | NASDAQ:KDNY, TSX:BLU, NASDAQ:BLU, | Discontinuing Coverage. | Biotechnology | Download | biotechnology |
08-11-2023 | CareRx Corp. | TSX-CRRX | 2Q-2023 Results: Slower Pace of Partnering, but Long-Term Trajectory Remains on Track | Healthcare Services | Download | healthcare-services |
08-11-2023 | Knight Therapeutics Inc. | TSX: GUD | Strong 2Q-2023. Temporary Dip Still Expected. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-11-2023 | Medexus Pharmaceuticals Inc. | TSX:MDP | Strong 1Q-2024 Results, with Help from the Timing of Orders and Competitor Stumbles | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-11-2023 | HLS Therapeutics Inc. | TSX: HLS | 2Q-2023 Top Line In Line. New Vascepa Challenges Crop Up. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-10-2023 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | No Additional Responses, But We Remain Believers. | Biotechnology | Download | biotechnology |
08-07-2023 | AbCellera Biologics Inc. | NASDAQ:ABCL | 2Q-2023 Results: Slower Pace of Partnering, but Long-Term Trajectory Remains on Track | Biotechnology | Download | biotechnology |
08-04-2023 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | 2Q Beat; Most Forward Metrics Positive (PSFs the Exception); 2023 Guidance Raised. | Biotechnology | Download | biotechnology |
08-01-2023 | Reunion Neuroscience Inc. | NASDAQ:REUN | Discontinuing Coverage. | Biotechnology | Download | biotechnology |
07-25-2023 | AbCellera Biologics Inc. | NASDAQ:ABCL | Site Visit and Update with Management | Biotechnology | Download | biotechnology |
07-17-2023 | OpSens Inc. | TSX:OPS | F3Q-2023 Results – Opto and Savvy In Line; OEM Sales Beat. Gross Margin Continues to Strengthen. | Medical Technology | Download | medical-technology |
06-28-2023 | Fusion Pharmaceuticals Inc. | NASDAQ:FUSN | Phase 1 Update. Slowly But (with potentially positive signs) Surely. | Biotechnology | Download | biotechnology |
06-26-2023 | Medexus Pharmaceuticals Inc. | TSX:MDP | 4Q-2023 Results: Improved Outlook and Sufficient Capital to Settle Near-Term Debt Obligations | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-19-2023 | HLS Therapeutics Inc. | TSX: HLS | Expect Changes to Improve Profitability and Balance Sheet as well as a Short Leash on Vascepa. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-12-2023 | Chinook Therapeutics Inc. | NASDAQ:KDNY | Our Top Pick Gets Taken Out. | Biotechnology | Download | biotechnology |
06-12-2023 | Chinook Therapeutics Inc. | NASDAQ:KDNY | Preview of Upcoming ERA Data. | Biotechnology | Download | biotechnology |
06-12-2023 | Fusion Pharmaceuticals Inc. | NASDAQ:FUSN | Who’s Hot? Global Actinium Supply Assessment. | Biotechnology | Download | biotechnology |
06-08-2023 | Repare Therapeutics Inc. | (NASDAQ:RPTX | Initial Lunresertib MonoTx ORR Lite, But With Other Encouraging Signals. | Biotechnology | Download | biotechnology |
06-08-2023 | Zymeworks Inc., Repare Therapeutics Inc., ASCO | NASDAQ:ZYME, NASDAQ:RPTX | ASCO Wrap. | Sector Reports | Download | sector-reports |
06-06-2023 | CareRx Corp. | TSX-CRRX | Site Visit and Forecast Update | Healthcare Services | Download | healthcare-services |
06-01-2023 | Reunion Neuroscience Inc. | NASDAQ:REUN | End of the Line for Reunion | Biotechnology | Download | biotechnology |
05-30-2023 | Viemed Healthcare Inc. | NASDAQ-VMD; TSX:VMD | Discontinuing Coverage | Healthcare Services | Download | healthcare-services |
05-30-2023 | CloudMD Software & Services Inc. | TSX-V:DOC | Discontinuing Coverage | Digital Health | Download | digital-health |
05-30-2023 | Newtopia Inc. | TSX-V:NEWU | Discontinuing Coverage | Digital Health | Download | digital-health |
05-30-2023 | BioSyent Inc. | TSX-V: RX | 1Q-2023 Results: Wholesaler Stocking in 4Q-2022 Leads to Weaker Quarter. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-26-2023 | AbCellera Biologics Inc. | NASDAQ: ABCL | AbCellera Scores a Sweet Deal | Biotechnology | Download | biotechnology |
05-22-2023 | Chinook Therapeutics Inc. | (NASDAQ: KDNY | Ionis Partnership, Zigakibart Phase 3 Trial Design and Clearing Up Some Misconceptions. | Biotechnology | Download | biotechnology |
05-18-2023 | Microbix Biosystems Inc. | TSX: MBX | Microbix Finds a Partner for Kinlytic | Medical Technology | Download | medical-technology |
05-17-2023 | Greenbrook TMS Inc. | NASDAQ: GBNH; TSX: GTMS | 1Q-2023. Positive Early Impact of Restructuring | Healthcare Services | Download | healthcare-services |
05-16-2023 | Hamilton Thorne Ltd. | TSX-V:HTL | Strong 1Q-2023 – Post COVID Bounce. | Healthcare Services | Download | healthcare-services |
05-15-2023 | Microbix Biosystems Inc. | TSX:MBX | 2Q-2023 Results: Margins Boost Bottom Line; Future DxTM Sales Removed from Forecasts | Medical Technology | Download | medical-technology |
05-12-2023 | Knight Therapeutics Inc. | TSX: GUD | Strong 1Q. Temporary Dip Still Expected. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-12-2023 | HLS Therapeutics Inc. | TSX: HLS | 1Q-23 In Line with BB Estimates. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-05-2023 | AbCellera Biologics Inc. | NASDAQ:ABCL | 1Q-2023 Revenues and Partnerships Light; Progress on Partnered Programs Shows Platform Potential | Biotechnology | Download | biotechnology |
05-05-2023 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | 1Q Strong; 2023 Guidance Raised; 2Q PSFs Flat; M&A Hopes on Hold? | Biotechnology | Download | biotechnology |
04-21-2023 | Repare Therapeutics Inc. | NASDAQ:RPTX | Camonsertib+PARPi: Encouraging Early Results in Heavily Pre-treated Patients. | Biotechnology | Download | biotechnology |
04-19-2023 | Greenbrook TMS Inc. | NASDAQ:GBNH; TSX: GTMS | 4Q-2022 Financial Results Lite but What will Restructuring Bring? | Healthcare Services | Download | healthcare-services |
04-17-2023 | Reunion Neuroscience Inc. | NASDAQ:REUN | Reunion’s Patent Dispute with Mindset | Biotechnology | Download | biotechnology |
04-12-2023 | Chinook Therapeutics Inc. | NASDAQ:KDNY | CHK-336 Phase 1 Halted, But Limited Impact on Our Valuation. | Biotechnology | Download | biotechnology |
04-10-2023 | Liminal BioSciences Inc. | NASDAQ:LMNL | Liminal Receives Unsolicited Transaction Proposal from Thomvest | Biotechnology | Download | biotechnology |
04-06-2023 | Bellus Health Inc. | NASDAQ:BLU; TSX:BLU | On the Path to Further Differentiation | Biotechnology | Download | biotechnology |
04-05-2023 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Small Biopsy Sub-Study Results Encouraging. | Biotechnology | Download | biotechnology |
03-31-2023 | Hamilton Thorne Ltd. | TSX-V:HTL | 4Q-2022 Results. Headwinds Looking to Become Tailwinds. | Healthcare Services | Download | healthcare-services |
03-28-2023 | OpSens Inc. | TSX:OPS | Savvy Move – Leveraging Core Tech in a New Indication With Big Differentiation. | Medical Technology | Download | medical-technology |
03-24-2023 | Knight Therapeutics Inc. | TSX: GUD | Strong 4Q-2022 Financial Results. Guidance Buffeted by Headwinds. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-23-2023 | BioSyent Inc. | TSX-V:RX | 4Q-2022 Results: Product Launch Preparations Impact Profitability | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-17-2023 | The Therapeutic Window | | The Therapeutic Window | Sector Reports | Download | sector-reports |
03-17-2023 | HLS Therapeutics Inc. | TSX: HLS | 4Q-2022 Results Impacted by FX; Vascepa Challenges Persist – 2023 Guidance C$22M-C$28M. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-15-2023 | Medexus Pharmaceuticals Inc. | TSX:MDP | New Credit Facilities a Positive | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-14-2023 | Miravo Healthcare | TSX:MRV | Discontinuing Coverage. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-13-2023 | CareRx Corp. | TSX: CRRX | 4Q-2022 Results In Line; Margins Under Pressure Due to Inflation | Healthcare Services | Download | healthcare-services |
03-09-2023 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Upcoming Catalysts and Model Update | Biotechnology | Download | biotechnology |
03-07-2023 | Greenbrook TMS Inc. | NASDAQ: GBNH, TSX: GTMS, | Restructuring Could Turn the Ship Around | Healthcare Services | Download | healthcare-services |
03-06-2023 | Viemed Healthcare Inc. | NASDAQ: VMD. TSX: VMD | 4Q-2022 Results – Returning to Pre-pandemic Growth Rates | Healthcare Services | Download | healthcare-services |
03-01-2023 | Mimi’s Rock Corp. | TSX-V | Discontinuing Coverage | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-01-2023 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | 4Q-2022 Results – Financials In Line; Most Forward Predictors Improving (after a weak 1Q-3Q period) | Biotechnology | Download | biotechnology |
02-28-2023 | Chinook Therapeutics Inc. | NASDAQ:KDNY | Disappointing ALIGN Readout Delay but Does Not Change Our Probability of Approval. | Biotechnology | Download | biotechnology |
02-22-2023 | AbCellera Biologics Inc. | NASDAQ:ABCL | 4Q-2022 Results: Light on Revenue, But Pipeline Momentum Builds | Biotechnology | Download | biotechnology |
02-20-2023 | Chinook Therapeutics Inc. | NASDAQ:KDNY | Travere’s Sparsentan Approved | Biotechnology | Download | biotechnology |
02-17-2023 | ESSA Pharma Inc. | NASDAQ:EPIX | ASCO GU. Combination Results Remain Strong; Monotherapy Weaker/Nuanced but Supportive | Biotechnology | Download | biotechnology |
02-17-2023 | Fusion Pharmaceuticals Inc. | NASDAQ:FUSN | Unconventional Accelerating Acquisition | Biotechnology | Download | biotechnology |
02-15-2023 | Reunion Neuroscience Inc. | NASDAQ:REUN; TSX:REUN | Phase 2 Initiation Remains on Track but Financing Overhang Remains. | Biotechnology | Download | biotechnology |
02-10-2023 | Microbix Biosystems Inc. | TSX: MBX | Weak 1Q-2023 Results Across the Business, But Looking Up in 2H-2023. | Medical Technology | Download | medical-technology |
02-10-2023 | Medexus Pharmaceuticals Inc. | TSX:MDP | 3Q-2023 Results – Operating Margins Continue to Improve | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-09-2023 | Greenbrook TMS Inc. | NASDAQ:GBNH; TSX-GTMS | Amendment and Drawdown on Credit Facility | Healthcare Services | Download | healthcare-services |
02-08-2023 | Titan Medical Inc. | NASDAQ:TMDI; TSX:TMD | Discontinuing Coverage | Medical Technology | Download | medical-technology |
01-26-2023 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | One Day….Two Positive IP Events. | Biotechnology | Download | biotechnology |
01-18-2023 | Miravo Healthcare | TSX:MRV | A Fair Take-out Valuation. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-18-2023 | Neovasc Inc. | NASDAQ:NVCN; TSX:NVCN | Very Honorable. | Medical Technology | Download | medical-technology |
01-11-2023 | Reunion Neuroscience Inc. | NASDAQ:REUN; TSX:REUN | Phase 1 Supports Target Product Profile. | Biotechnology | Download | biotechnology |
01-04-2023 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Nice Sunset(tlement) | Biotechnology | Download | biotechnology |
12-23-2022 | Microbix Biosystems Inc. | TSX:MBX | Disappointing 4Q-2022 Results and More Cautious Near-Term Outlook | Medical Technology | Download | medical-technology |
12-20-2022 | Zymeworks Inc. | NASDAQ:ZYME | Top-Line HERIZON-BTC-01 Results Positive | Biotechnology | Download | biotechnology |
12-19-2022 | Top Ideas | | 2023 Top Ideas | Sector Reports | Download | sector-reports |
12-12-2022 | Zymeworks Inc. | NASDAQ:ZYME | Combo Efficacy a Bit Lower; Still Competitive | Biotechnology | Download | biotechnology |
12-06-2022 | CareRx Corp. | TSX-CRRX | Critical Mass in Place, Looks Primed for Sustained Growth | Healthcare Services | Download | healthcare-services |
12-05-2022 | Mimi’s Rock Corp. | TSX-V:MIMI | Acquisition by FitLife Brands | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-28-2022 | Reunion Neuroscience Inc. | NASDAQ:REUN; TSX:REUN, | Reunion Coverage Transition: Continue to Have ‘High’ Expectations. | Biotechnology | Download | biotechnology |
11-23-2022 | Hamilton Thorne Ltd. | TSX-V:HTL | 3Q-2022 Results Mixed. | Healthcare Services | Download | healthcare-services |
11-17-2022 | BioSyent Inc. | TSX-V:RX | 3Q-2022 Results: New Launches Slow but Gathering Steam | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-16-2022 | CloudMD Software & Services Inc. | TSX-V:DOC | 3Q-2022 Results Miss but Improving Margins and Pipeline Promising | Digital Health | Download | digital-health |
11-16-2022 | Miravo Healthcare | TSX:MRV | 3Q-2022 Results Beat. Remaining on Sidelines Due to Patent Cliffs and Debt. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-11-2022 | Knight Therapeutics Inc. | TSX: GUD | 3Q-2022 Financial Results. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-10-2022 | HLS Therapeutics Inc. | TSX: HLS | 3Q-2022 Results Mixed – Is That an Inflection we See on the Horizon? | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-10-2022 | Medexus Pharmaceuticals Inc. | TSX:MDP | 2Q-2023 Results – Strong U.S. Sales Drive Outperformance | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-10-2022 | Greenbrook TMS Inc. | NASDAQ:GBNH; TSX-GTMS | 3Q-2022 Results Mixed – Strong Top Line with Synergies Forecast | Healthcare Services | Download | healthcare-services |
11-09-2022 | AbCellera Biologics Inc. | NASDAQ:ABCL | 3Q-2022 Results: Bebtelovimab Runs its Course; Program Starts Slow, but Downstream Participation Increases. | Biotechnology | Download | biotechnology |
11-09-2022 | Mimi’s Rock Corp. | TSX-V:MIMI | 3Q-2022 Results In Line. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-04-2022 | Chinook Therapeutics Inc. | NASDAQ:KDNY | ASN Data: Class-Leading Profiles Further Validated. | Biotechnology | Download | biotechnology |
11-03-2022 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | 3Q-2022 Lupkynis Sales Miss. Guidance Cut (2022)/Low (2023) – Back to School. | Biotechnology | Download | biotechnology |
11-03-2022 | Viemed Healthcare Inc. | NASDAQ-VMD; TSX-VMD; | 3Q-2022 Results – Early Signs of Margin Expansion | Healthcare Services | Download | healthcare-services |
10-31-2022 | ESSA Pharma Inc. | NASDAQ:EPIX | Never a Straight Line – Janssen Suspension of Enrollment Likely Just a Speed Bump We Believe. | Biotechnology | Download | biotechnology |
10-26-2022 | ESSA Pharma Inc. | NASDAQ:EPIX | Back on Track – Initial Combo Efficacy Results Beat Benchmark and Support EPI-7386 Biology. | Biotechnology | Download | biotechnology |
10-24-2022 | Zymeworks Inc. | NYSE:ZYME | Busy Week Changes Investment Thesis – More Risk; More (Potential) Reward. | Biotechnology | Download | biotechnology |
10-17-2022 | Chinook Therapeutics Inc. | NASDAQ:KDNY | Travere’s Regulatory Setback and ASN Abstracts. | Biotechnology | Download | biotechnology |
09-29-2022 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | ABILITY Update Mixed. Emerging MDNA11 Profile Remains Positive – Continues to Support an Undervaluation Thesis. | Biotechnology | Download | biotechnology |
09-20-2022 | Medexus Pharmaceuticals Inc. | TSX:MDP | Treosulfan Delayed Again; Downgrading to Sell | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-24-2022 | BioSyent Inc. | TSX-V:RX | 2Q-2022 Results Miss Due to Channel Inventory Adjustment | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-24-2022 | CloudMD Software & Services Inc. | TSX-V:DOC | 2Q-2022 Results Miss; Downgrading on Growth and Balance Sheet Concerns | Digital Health | Download | digital-health |
08-24-2022 | Hamilton Thorne Ltd. | TSX-V:HTL | 2Q-2022 Review. Performing Well in a FX- and Supply Chain-Challenged Environment | Healthcare Services | Download | healthcare-services |
08-16-2022 | Mimi’s Rock Corp. | TSX-V:MIMI | Strong 2Q-2022 Results and Improved Outlook | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-16-2022 | Miravo Healthcare | TSX:MRV | 2Q-2022 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-16-2022 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | In a Good Place – Financially, Clinically and Biologically | Biotechnology | Download | biotechnology |
08-15-2022 | Knight Therapeutics Inc. | TSX:GUD | 2Q-2022 Results Beat Estimates | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-15-2022 | HLS Therapeutics Inc. | TSX:HLS | 2Q-2022 Results In Line. Vascepa Growth Estimate Light for Remainder of 2022 | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-12-2022 | Microbix Biosystems Inc. | TSX:MBX | 3Q-2022 Results In Line and Large QAPs Deal Adds to Future Growth | Medical Technology | Download | medical-technology |
08-12-2022 | Neovasc Inc. | NASDAQ:NVCN; TSX:NVCN | 2Q-2022 Results – Green Shoots. | Medical Technology | Download | medical-technology |
08-12-2022 | Reunion Neuroscience Inc. | NASDAQ:REUN; TSX:REUN | Focus Turns to FT-104 | Biotechnology | Download | biotechnology |
08-11-2022 | Newtopia Inc. | TSX-V:NEWU | 2Q-2022 Results – Weak Quarter but Pipeline has Potential | Digital Health | Download | digital-health |
08-11-2022 | AbCellera Biologics Inc. | NASDAQ:ABCL | 2Q-2022 Results: Cashed Up for Growth. | Biotechnology | Download | biotechnology |
08-10-2022 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 1Q-2023 Results – Revenues Beat on U.S. Strength | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-05-2022 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | 2Q Lupkynis Sales Beat. PSFs Low | Biotechnology | Download | biotechnology |
08-04-2022 | Viemed Healthcare Inc. | NASDAQ:VMD, TSX:VMD | 2Q-2022 Results – Core Business Pushing Through | Healthcare Services | Download | healthcare-services |
08-04-2022 | Greenbrook TMS Inc. | NASDAQ:GBNH, TSX:GTMS | 2Q Impacted by Headwinds which are Easing; Moving Toward a Sweet Spot | Healthcare Services | Download | healthcare-services |
07-28-2022 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | ABILITY Update – Incremental; Continues to Point in Right Direction | Biotechnology | Download | biotechnology |
07-28-2022 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | A Jab from PTAB | Biotechnology | Download | biotechnology |
07-26-2022 | HLS Therapeutics Inc. | TSX:HLS | Largest Province on Board with Vascepa | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-25-2022 | Liminal BioSciences Inc. | NASDAQ:LMNL | Limited Pipeline Potential and Insufficient Cash Runway to Reach Clinical Catalysts | Biotechnology | Download | biotechnology |
07-15-2022 | Greenbrook TMS Inc. | NASDAQ:GBNH, TSX:GTMS | Rubber….Meet Road. Closing of Success TMS Acquisition and US$75 Million Credit Facility | Healthcare Services | Download | healthcare-services |
07-13-2022 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | More Clarity May Bring Suitors Closer | Biotechnology | Download | biotechnology |
07-06-2022 | Mimi’s Rock Corp. | TSX-V:MIMI | 4Q-2021 and 1Q-2022 Results Miss | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-05-2022 | Neovasc Inc. | NASDAQ:NVCN; TSX:NVCN | Historical Challenges Mask Enormous Upside Potential – Tackling Two Gaps in CVD* Care | Medical Technology | Download | medical-technology |
06-28-2022 | ESSA Pharma Inc. | NASDAQ:EPIX | EPI-7386 Phase 1a Update – Mixed Results | Biotechnology | Download | biotechnology |
06-23-2022 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 4Q-2022 Results – Earnings Beat; Treosulfan Uncertainty Remains | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-22-2022 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | FY-2022 Results. ABILITY Update | Biotechnology | Download | biotechnology |
06-22-2022 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | End of Phase 2 Meeting with FDA | Biotechnology | Download | biotechnology |
06-06-2022 | Microbix Biosystems Inc. | TSX:MBX | Microbix Initiation: Steady Cash Flow and Significant Growth Potential | Medical Technology | Download | medical-technology |
06-06-2022 | ESSA Pharma Inc. | NASDAQ:EPIX | EPI-7386 Phase 1a Results Preview | Biotechnology | Download | biotechnology |
06-01-2022 | CloudMD Software & Services Inc. | TSX-V:DOC | 1Q-2022 Results Beat Expectations but Macro Challenges Weigh | Digital Health | Download | digital-health |
05-27-2022 | Zymeworks Inc. | NYSE:ZYME | ASCO 2022 Data Positive/Mixed | Biotechnology | Download | biotechnology |
05-20-2022 | Chinook Therapeutics Inc. | NASDAQ:KDNY | ERA Data: Best-in-Class Profile Emerging for Atrasentan | Biotechnology | Download | biotechnology |
05-20-2022 | BioSyent Inc. | TSX-V:RX | 1Q-2022 Results – No Surprises | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-20-2022 | Hamilton Thorne Ltd. | TSX-V:HTL | 1Q-2022 Impacted by Transient Issues. Still a Great Company – BUY the Dip | Healthcare Services | Download | healthcare-services |
05-19-2022 | Newtopia Inc. | TSX-V:NEWU | 1Q-2022 Results in Line; Growth Challenges Continue, Downgrade to ACCUMULATE | Healthcare Services | Download | healthcare-services |
05-19-2022 | Chinook Therapeutics Inc. | NASDAQ:KDNY | ERA Data: BION-1301 Continues to Impress | Biotechnology | Download | biotechnology |
05-17-2022 | Greenbrook TMS Inc. | NASDAQ:GBNH, TSX:GTMS | 1Q-2021 Success…and Buying Success | Healthcare Services | Download | healthcare-services |
05-17-2022 | Miravo Healthcare | TSX:MRV | Mixed 1Q-2022 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-13-2022 | Miravo Healthcare | TSX:MRV | Another Shoe Drops Unexpectedly – Reversal Possible, but More Likely Not | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-13-2022 | Knight Therapeutics Inc. | TSX:GUD | Strong 1Q-2022 – Raising Rating to BUY | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-11-2022 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Solid 1Q-2022 Amidst Omicron | Biotechnology | Download | biotechnology |
05-11-2022 | AbCellera Biologics Inc. | NASDAQ:ABCL | 1Q-2022 COVID Sales Strong | Biotechnology | Download | biotechnology |
05-10-2022 | Mimi’s Rock Corp. | TSX-V:MIMI | Filing Delay and Cease Trade Order | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-09-2022 | AbCellera Biologics Inc. | NASDAQ:ABCL | 1Q-2022 Financial Results Preview | Biotechnology | Download | biotechnology |
05-05-2022 | Chinook Therapeutics Inc. | NASDAQ:KDNY | ERA Abstracts: Gearing Up for Key Readouts for Atrasentan and BION-1301 | Biotechnology | Download | biotechnology |
05-02-2022 | HLS Therapeutics Inc. | TSX:HLS | In Support of C$250-$300M Peak Vascepa Sales (and near-term sales acceleration) | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-02-2022 | Zymeworks Inc. | NYSE:ZYME | Non-Binding Proposal to Acquire ZYME; ASCO Preview | Biotechnology | Download | biotechnology |
04-26-2022 | HLS Therapeutics Inc. | TSX:HLS | Time for the Rubber to Hit the Road | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-12-2022 | Repare Therapeutics Inc. | NASDAQ:RPTX | The Rodney Dangerfield of Oncology Drugs | Biotechnology | Download | biotechnology |
04-08-2022 | Hamilton Thorne Ltd. | TSX-V:HTL | 4Q-2021 Results Beat | Healthcare Services | Download | healthcare-services |
04-07-2022 | Newtopia Inc. | TSX-V:NEWU | 4Q-2021 Results – Weighed Down by Omicron; Upgrading to BUY on Value | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
04-04-2022 | Greenbrook TMS Inc. | NASDAQ:GBNH, TSX:GTMS | 4Q-2021 in Line. Focus Shifts to Increasing Utilization; Optimizing Costs; Strengthening Balance Sheet | Healthcare Services | Download | healthcare-services |
03-29-2022 | Miravo Healthcare | TSX:MRV | 4Q-2021 Results Mixed | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-25-2022 | Knight Therapeutics Inc. | TSX:GUD | 4Q-2021 Results; 2022 Guidance Low due to Unanticipated LATAM Risks | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-18-2022 | HLS Therapeutics Inc. | TSX:HLS | 4Q-2021 Missed Consensus; Vascepa On the Cusp | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-10-2022 | BioSyent Inc. | TSX-V:RX | 4Q-2021 Results – Chugging Along | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-09-2022 | Viemed Healthcare Inc. | NASDAQ:VMD, TSX:VMD | 4Q-2021 Results – Omicron Bump | Healthcare Services | Download | healthcare-services |
03-08-2022 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Flipping the IPR Probabilities | Biotechnology | Download | biotechnology |
03-01-2022 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | 4Q-2021 Results Inline; Guidance Low | Biotechnology | Download | biotechnology |
02-28-2022 | AbCellera Biologics Inc. | NASDAQ:ABCL | FY-2021 Results: Shifting Focus to Program Starts but Strategy Unchanged | Biotechnology | Download | biotechnology |
02-22-2022 | The Therapeutic Window | | The Therapeutic Window | Sector Reports | Download | sector-reports |
02-17-2022 | Reunion Neuroscience Inc. | NASDAQ:REUN; TSX:REUN | FY-3Q Results – Clinic Buildout Distracting from FT-104 | Biotechnology | Download | biotechnology |
02-11-2022 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 3Q-2022 Results – Earnings Beat due to Order Timing | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-10-2022 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Pre-earnings COVID Adjustment | Biotechnology | Download | biotechnology |
02-01-2022 | Zymeworks Inc. | NYSE:ZYME | Dilutive Financing a Risk Balancing Act | Biotechnology | Download | biotechnology |
01-25-2022 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | One Company’s Misfortune… | Biotechnology | Download | biotechnology |
01-14-2022 | MindBeacon Holdings Inc. | TSX:MBCN | Discontinuing Coverage | Digital Health | Download | digital-health |
12-23-2021 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | ABILITY Results Early, Limited but Encouraging vs Other IL-2 Agonists | Biotechnology | Download | biotechnology |
12-22-2021 | CloudMD Software & Services | TSX-V:DOC | Every Cloud Has a Silver Lining | Digital Health | Download | digital-health |
12-19-2021 | Abcellera Biologics | NASDAQ:ABCL | AbCellera Initiation: Just Getting Started | Biotechnology | Download | biotechnology |
12-17-2021 | Top Ideas | | 2022 Top Ideas | Sector Reports | Download | sector-reports |
12-14-2021 | Zymeworks Inc. | NYSE:ZYME | We Think the Market is Wrong Thinking ZYME Doesn’t Work | Biotechnology | Download | biotechnology |
12-13-2021 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Quick Reaction: SOOTHE-ing Results | Biotechnology | Download | biotechnology |
12-10-2021 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | AURORA 2 3-Year Safety Results – As Good as it Gets Without a Biopsy | Biotechnology | Download | biotechnology |
12-06-2021 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Additional XEN1101 Data Does Not Dampen Our Enthusiasm | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-01-2021 | Mimi’s Rock Corp. | TSX-V:MIMI | 3Q-2021 Results: FX and Supply Chain Headwinds Result in Weaker Quarter | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-23-2021 | Hamilton Thorne Ltd. | TSX-V:HTL | Mixed 3Q-2021 Results. Underlying Business Remains Strong – Pandemic Supply Chain Issues Impacted Revenues and Margins | Healthcare Services | Download | healthcare-services |
11-19-2021 | BioSyent Inc. | TSX-V:RX | 3Q-2021 Results – Mixed Quarter | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-17-2021 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | Discontinuing Coverage | Biotechnology | Download | biotechnology |
11-17-2021 | Miravo Healthcare | TSX:MRV | 3Q-2021 Results Mixed. Remains Undervalued | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-16-2021 | MindBeacon Holdings Inc. | TSX:MBCN | 3Q-2021 Results; Moving Target to Acquisition Price, Rating to HOLD | Digital Health | Download | digital-health |
11-15-2021 | Titan Medical Inc. | NASDAQ:TMDI; TSX:TMD | Late in the Game Delay | Medical Technology | Download | medical-technology |
11-12-2021 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 2Q-2022 Results – No Major Surprises | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-12-2021 | Knight Therapeutics Inc. | TSX:GUD | Strong 3Q-2021 Financial Results Boosted by Antifungals | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-11-2021 | Newtopia Inc. | TSX-V:NEWU | 3Q-2021 Results – Material COVID Impact Continues | Digital Health | Download | digital-health |
11-11-2021 | Greenbrook TMS Inc. | NASDAQ:GBNH, TSX:GTMS | Summer Fun Drives Lite 3Q-2021 – COVID Slump Should Turn to COVID Bump | Healthcare Services | Download | healthcare-services |
11-10-2021 | Reunion Neuroscience Inc. | NASDAQ:REUN; TSX:REUN | COMPASS Tracks South: COMP360 Phase 2b Results Generally Positive but Add Some Uncertainty | Biotechnology | Download | biotechnology |
11-05-2021 | HLS Therapeutics Inc. | TSX:HLS | 3Q-2021 Results Mixed. PCPA Negotiations a Tough Slog – Blockbuster Tantalizingly Close | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-05-2021 | Chinook Therapeutics Inc. | NASDAQ:KDNY | Additional BION-1301 Data. | Biotechnology | Download | biotechnology |
11-04-2021 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | 3Q-2021 Early Launch Tracking Well. Takeover Rumors Impacting SP | Biotechnology | Download | biotechnology |
11-03-2021 | Viemed Healthcare Inc. | NASDAQ:VMD, TSX:VMD | 3Q-2021 Results Beat Guidance | Healthcare Services | Download | healthcare-services |
10-11-2021 | Repare Therapeutics Inc. | NASDAQ:RPTX | Early RP-3500 Results Nuanced – Overall Supportive of Best-in-Class Potential | Biotechnology | Download | biotechnology |
10-04-2021 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | XEN1101 Hits a Homerun | Biotechnology | Download | biotechnology |
10-01-2021 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | Moving Target to Acquisition Price (US$18.50); Rating to HOLD | Biotechnology | Download | biotechnology |
10-01-2021 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | HOLD on Stock Appreciation | Biotechnology | Download | biotechnology |
10-01-2021 | Greenbrook TMS Inc. | NASDAQ:GBNH, TSX:GTMS | Achieve TMS East/Central Acquisition Gets GBNH to Target, Supported by Financing | Healthcare Services | Download | healthcare-services |
09-30-2021 | Repare Therapeutics Inc. | NASDAQ:RPTX | Initial Phase 1/2 Results Preview | Biotechnology | Download | biotechnology |
09-22-2021 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | ABILITY Preview | Biotechnology | Download | biotechnology |
09-16-2021 | Zymeworks Inc. | NYSE:ZYME | Maturing Nicely | Biotechnology | Download | biotechnology |
09-14-2021 | Zymeworks Inc. | NYSE:ZYME | Encouraging Initial Zanidatamab 1L GEA Phase 2 Data | Biotechnology | Download | biotechnology |
09-13-2021 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | SOOTHE Administrative Interim Points to Positive Topline in 4Q | Biotechnology | Download | biotechnology |
08-26-2021 | BioSyent Inc. | TSX-V:RX | 2Q-2021 Results – Revenues Beat | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-18-2021 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 1Q-2022 Results – U.S.Business Continues to Disappoint | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-17-2021 | Chinook Therapeutics Inc. | NASDAQ:KDNY | Travere’s Sparsentan Validates ETA Inhibition in IgAN | Biotechnology | Download | biotechnology |
08-17-2021 | HLS Therapeutics Inc. | TSX:HLS | Wiser to Co-Promote with Pfizer | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-16-2021 | Knight Therapeutics Inc. | TSX:GUD | Strong 2Q-2021 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-13-2021 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | 2Q-2021 Results. Upcoming Phase 2 (x2). Merck Gefapixant FDA Delay. | Biotechnology | Download | biotechnology |
08-10-2021 | Miravo Healthcare | TSX:MRV | 2Q-2021 Results Beat | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-09-2021 | Reunion Neuroscience Inc. | NASDAQ:REUN; TSX:REUN | Initiation: The high Way to Happiness | Biotechnology | Download | biotechnology |
08-09-2021 | Greenbrook TMS Inc. | NASDAQ:GBNH, TSX:GTMS | 2Q-2021 Financial Results in Line | Healthcare Services | Download | healthcare-services |
08-06-2021 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | 2Q-2021 Results – Lupkynis Beats | Biotechnology | Download | biotechnology |
08-06-2021 | Mimi’s Rock Corp. | TSX-V:MIMI | 2Q-2021 Results – Revenues Down, but Profitability Up | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-05-2021 | HLS Therapeutics Inc. | TSX:HLS | 2Q-2021 Results. Vascepa Lite with COVID – Catalysts Ahead | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-04-2021 | Medexus Pharmaceuticals Inc. | TSX:MDP | Treosulfan Delayed; Downgrading to HOLD | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-04-2021 | Viemed Healthcare Inc. | NASDAQ:VMD, TSX:VMD | 2Q-2021 Financial Results | Healthcare Services | Download | healthcare-services |
07-29-2021 | Greenbrook TMS Inc. | NASDAQ:GBNH, TSX:GTMS | Update and 2Q-2021 Results Preview. Adding (a bit of) Spravato to our Forecasts | Healthcare Services | Download | healthcare-services |
07-29-2021 | MindBeacon Holdings Inc. | TSX:MBCN | 2Q-2021 Financial Results Margin Pressures Likely Transient | Digital Health | Download | digital-health |
07-15-2021 | Hamilton Thorne Ltd. | TSX-V:HTL | IVFtech: A Bigger Accretive and Strategic Acquisition | Healthcare Services | Download | healthcare-services |
07-13-2021 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Setting the Stage for XEN1101 | Biotechnology | Download | biotechnology |
06-18-2021 | Medexus Pharmaceuticals Inc. | TSX:MDP | 4Q-2021 Financial Results Lite. No Alarms, Some Surprises | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-09-2021 | Chinook Therapeutics Inc. | NASDAQ:KDNY | BION-1301: Early POC Efficacy in IgAN | Biotechnology | Download | biotechnology |
06-07-2021 | Liminial BioSciences Inc | NASDAQ:LMNL | Ryplazim Approved and Fezagepras Put on Hold | Biotechnology | Download | biotechnology |
05-28-2021 | BioSyent Inc. | TSX-V:RX | Strong 1Q-2021 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-28-2021 | Mimi’s Rock Corp. | TSX-V:MIMI | 1Q-2021 Results: FX and Discounts Mask Volume Growth | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-26-2021 | Chinook Therapeutics Inc. | NASDAQ:KDNY | Competitor Stumbles, but Limited Readthrough to Chinook | Biotechnology | Download | biotechnology |
05-26-2021 | Hamilton Thorne Ltd. | TSX-V:HTL | 1Q -2021 Results: Mixed Quarter but Overall Better Than Forecast | Healthcare Services | Download | healthcare-services |
05-21-2021 | Newtopia Inc. | TSX:NEWU | 1Q-2021 Results – Softer, but Expected | Digital Health | Download | digital-health |
05-21-2021 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Double Bonus – AURORA 2 Interim Results | Biotechnology | Download | biotechnology |
05-18-2021 | Liminal BioSciences Inc. | NASDAQ:LMNL | Plasma Business Divestment | Biotechnology | Download | biotechnology |
05-18-2021 | Miravo Healthcare | TSX:MRV | Mixed 1Q-2021 Results. EV/EBITDA remains low; D/E Remains High | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-17-2021 | Knight Therapeutics Inc. | TSX:GUD | 1Q-2021 Financial Results – Most Parts Moving in the Right Direction | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-14-2021 | MindBeacon Holdings Inc. | TSX:MBCN | 1Q-2021 Financial Results: Some Gives and Takes | Digital Health | Download | digital-health |
05-07-2021 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | First Quarter Lupkynis Sales Lite, but More Upside Than Downside at $12.34 | Biotechnology | Download | biotechnology |
05-06-2021 | HLS Therapeutics Inc. | TSX:HLS | 1Q-2021 Results In Line. Vascepa Momentum Building | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-05-2021 | Hamilton Thorne Ltd. | TSX-V:HTL | Another Strategic Acquisition with Good Synergy Potential | Healthcare Services | Download | healthcare-services |
05-05-2021 | Viemed Healthcare Inc. | NASDAQ:VMD, TSX:VMD | 1Q-2021 Financial Results In-Line 5 | Healthcare Services | Download | healthcare-services |
04-30-2021 | Mimi’s Rock Corp. | TSX-V:MIMI | 4Q-2020 Financial Results: Amazon Prime Day Doesn’t Deliver | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-29-2021 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | R&D Day: More Monotx Responses- Wait Begins for Combo Results | Biotechnology | Download | biotechnology |
04-26-2021 | Knight Therapeutics Inc. | TSX:GUD | Exelon Acquisition In Line With Our Valuation of GUD – Upside Possible | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-23-2021 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | Discontinuing Coverage | Healthcare Services | Download | healthcare-services |
04-19-2021 | Titan Medical Inc. | NASDAQ:TMDI; TSX:TMD | TMDI Initiation – Differentiated, Entering the Final Stretch | Medical Technology | Download | medical-technology |
04-15-2021 | Chinook Therapeutics Inc. | NASDAQ:KDNY | BION-1301 Coming Into Focus | Biotechnology | Download | biotechnology |
04-09-2021 | Repare Therapeutics Inc. | NASDAQ:RPTX | Promising 2nd Program Unveiled | Biotechnology | Download | biotechnology |
04-08-2021 | Hamilton Thorne Ltd. | TSX-V:HTL | 4Q-2020 Financial Results | Healthcare Services | Download | healthcare-services |
04-08-2021 | Newtopia Inc. | TSX:NEWU | 4Q-2020 Financial Results | Digital Health | Download | digital-health |
04-01-2021 | Greenbrook TMS Inc. | NASDAQ:GBNH, TSX:GTMS | 4Q-2020 Financial Results – Short term pain for long term gain | Healthcare Services | Download | healthcare-services |
03-29-2021 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | Don’t Look There…Look Here! | Biotechnology | Download | biotechnology |
03-26-2021 | Knight Therapeutics Inc. | TSX:GUD | 4Q-2020 Financial Results – A Peek at Somewhat Normal | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-22-2021 | Chinook Therapeutics Inc. | NASDAQ:KDNY | Chinook Initiation: Catch the Wind | Biotechnology | Download | biotechnology |
03-10-2021 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q2 F2012 results in line with estimates. Price target to $2.25 | Biotechnology | Download | biotechnology |
03-08-2021 | Novelion Therapeutics Inc. | NASDAQ:NVLN | 1Q-2019 Financial Results | Biotechnology | Download | biotechnology |
03-08-2021 | HLS Therapeutics Inc. | TSX:HLS | Vascepa Approved by Health Canada with Slightly Broader Label vs U.S. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-05-2021 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 3Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-23-2021 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | Treosulfan Acquisition, Financing | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-19-2021 | Hamilton Thorne Ltd. | TSX-V:HTL | 4Q-2020 Preliminary Results | Healthcare Services | Download | healthcare-services |
02-17-2021 | The Therapeutic Window | | The Therapeutic Window | Sector Reports | Download | sector-reports |
02-12-2021 | ESSA Pharma Inc. | NASDAQ:EPIX | Initial EPI-7386 Phase 1 Results. Check. Check. Bonus | Biotechnology | Download | biotechnology |
01-29-2021 | Liminal BioSciences Inc. | NASDAQ:LMNL | Ryplazim Shelved | Biotechnology | Download | biotechnology |
01-28-2021 | Zymeworks Inc. | NYSE:ZYME | Slow (but steady may win the race) | Biotechnology | Download | biotechnology |
01-25-2021 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | LUPKYNIS (voclosporin) Approved | Biotechnology | Download | biotechnology |
01-18-2021 | Zymeworks Inc. | NYSE:ZYME | Incremental Zanidatamab Update. Key ZW49 Data Expected January 27 | Biotechnology | Download | biotechnology |
12-23-2020 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | Dropped Ball or Hardball? | Healthcare Services | Download | healthcare-services |
12-17-2020 | Fusion Pharmaceuticals Inc. | NASDAQ: FUSN | Hammer Time | Biotechnology | Download | biotechnology |
12-15-2020 | Top Ideas | | 2021 Top Ideas | Sector Reports | Download | sector-reports |
12-13-2020 | HLS Therapeutics Inc. | TSX:HLS | Encouraging Early COVID-19 Signal | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-08-2020 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | Skinny ASH. But Tril (and CD47) Still Well Positioned | Biotechnology | Download | biotechnology |
12-06-2020 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | TT1-622:ASH Incremental/Mixed. Overall Profile Remains Robust | Biotechnology | Download | biotechnology |
11-27-2020 | BioSyent Inc. | TSX-V:RX | 3Q-2020 Financial Results. Awaiting New Product Ramp Ups | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-24-2020 | Mimi’s Rock Corp. | TSX-V:MIMI | 3Q-2020 Financial Results. Not Prime Time but Recovery Continues | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-20-2020 | Hamilton Thorne Ltd. | TSX-V:HTL | 3Q-2020 Financial Results. Baby Bounce | Healthcare Services | Download | healthcare-services |
11-19-2020 | Liminal BioSciences Inc. | NASDAQ:LMNL | Valuation Update Due to Recent Developments that Increase Risk | Biotechnology | Download | biotechnology |
11-18-2020 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 2Q-2021 Financial Results. Uphill, but a Steady Climb Nevertheless | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-17-2020 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 3Q-2020 Financial Results. A Beat, With Some Help, During COVID | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-17-2020 | HLS Therapeutics Inc. | TSX:HLS | Perseris Pop | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-16-2020 | Knight Therapeutics Inc. | TSX:GUD | 3Q-2020 Financial Results. Brisk COVID-19 Headwinds Continue | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-16-2020 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 3Q-2020 Financial Results. Pushing Through the Pandemic | Healthcare Services | Download | healthcare-services |
11-16-2020 | Cipher Pharmaceuticals Inc. | TSX:CPH | 3Q-2020 Financial Results. Lack of Near-Term Drivers | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-13-2020 | Newtopia Inc. | TSX:NEWU | 3Q-2020 Financial Results | Digital Health | Download | digital-health |
11-12-2020 | Greenbrook TMS Inc. | TSX:GTMS | 3Q-2020 Financial Results | Healthcare Services | Download | healthcare-services |
11-06-2020 | HLS Therapeutics Inc. | TSX:HLS | 3Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-06-2020 | VieMed Healthcare Inc. | NASDAQ:VMD, TSX:VMD | 3Q-2020 Financial Results | Healthcare Services | Download | healthcare-services |
11-03-2020 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | VOS Comes up Dry (LN remains Attractive but AUPH less Diversified) | Biotechnology | Download | biotechnology |
10-19-2020 | VieMed Healthcare Inc. | NASDAQ:VMD, TSX:VMD | Breathing Well | Healthcare Services | Download | healthcare-services |
10-16-2020 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | MdNA55 Phase 3 Shaping Up | Biotechnology | Download | biotechnology |
10-05-2020 | Liminal BioSciences Inc. | NASDAQ:LMNL | Liminal – Hold on Outlook and Valuation | Biotechnology | Download | biotechnology |
09-17-2020 | Repare Therapeutics Inc. | NASDAQ:RPTX | Big Lethal – Large-Scale Platform to Lead the Next Major Land Grab in Oncology | Biotechnology | Download | biotechnology |
09-17-2020 | HLS Therapeutics Inc. | TSX:HLS | Diversified High Margin Royalty Acquisition – Buffers Near-term COVID-19 Impact With Potential Long-term Upside | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-09-2020 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | Trillium Therapeutics Inc. (NASDAQ:TRIL, US$9.46; TSX:TRIL, C$12.52) | Biotechnology | Download | biotechnology |
09-08-2020 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Back in the (Competitive) Saddle | Biotechnology | Download | biotechnology |
09-01-2020 | HLS Therapeutics Inc. | TSX:HLS | Additional Support for Vascepa. Competitor Fails Again | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-27-2020 | Mimi’s Rock Corp. | TSX-V:MIMI | 2Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-27-2020 | BioSyent Inc. | TSX-V:RX | 2Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-25-2020 | Greenbrook TMS Inc. | NASDAQ:GBNH, TSX:GTMS | TMS Device Vendors Doing Well. Who’s Next? | Healthcare Services | Download | healthcare-services |
08-21-2020 | Hamilton Thorne Ltd. | TSX-V:HTL | 2Q-2020 Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
08-14-2020 | Knight Therapeutics Inc. | TSX:GUD | 2Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-14-2020 | Cipher Pharmaceuticals Inc. | TSX:CPH | 2Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-13-2020 | Newtopia Inc. | TSX-V:NEWU | 2Q-2020 Financial Results | Digital Health | Download | digital-health |
08-13-2020 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 1Q-2021 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-13-2020 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Pipeline Update and Epilepsy Market Overview | Biotechnology | Download | biotechnology |
08-12-2020 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 2Q-2020 Financial Results | Healthcare Services | Download | healthcare-services |
08-11-2020 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 2Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-07-2020 | HLS Therapeutics Inc. | TSX:HLS | 2Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-06-2020 | Newtopia Inc. | TSX-V:NEWU | Teladoc-Livongo Merger Brings Attractive NEWU Valuation into Spotlight | Digital Health | Download | digital-health |
08-06-2020 | Greenbrook TMS Inc. | TSX:GTMS | 2Q-2020 Results | Healthcare Services | Download | healthcare-services |
07-21-2020 | HLS Therapeutics Inc. | TSX:HLS | Good Pricing Outcome for Vascepa | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-10-2020 | Zymeworks Inc. | NYSE:ZYME | 1H-2020 Clinical and Corporate Update | Biotechnology | Download | biotechnology |
07-09-2020 | Newtopia Inc. | TSX-V:NEWU | 1Q-2020 Financial Results | Digital Health | Download | digital-health |
07-09-2020 | HLS Therapeutics Inc. | TSX:HLS | Drug Pricing/Reimbursement Uncertainty in Canada – Bloom Burton’s Conservative Vascepa Pricing Assumptions Mitigate Valuation Risk | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-06-2020 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | No Relief from RELIEF – Primary Endpoint Missed. Still in the Race, But Substantially Higher Risk | Biotechnology | Download | biotechnology |
07-02-2020 | Mimi’s Rock Corp. | TSX-V:MIMI | 1Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-29-2020 | Knight Therapeutics Inc. | TSX:GUD | 1Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-24-2020 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 4Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-17-2020 | Newtopia Inc. | TSX-V:NEWU | 4Q-2019 Financial Results | Digital Health | Download | digital-health |
06-14-2020 | Zymeworks Inc. | NYSE:ZYME | Initiation. No Better ZYME Than the Present | Biotechnology | Download | biotechnology |
06-10-2020 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Another Brick in the Wall of Differentiation and Other News | Biotechnology | Download | biotechnology |
06-08-2020 | Mimi’s Rock Corp. | TSX-V:MIMI | 4Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-02-2020 | HLS Therapeutics Inc. | TSX:HLS | Saladax MyCare Distribution Agreement | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-01-2020 | Hamilton Thorne Ltd. | TSX-V:HTL | 1Q-2020 Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
05-29-2020 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | Quick ASCO Take – MDNA55 | Biotechnology | Download | biotechnology |
05-29-2020 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | Quick ASCO Take –MDNA11 IL-2 Superkine | Biotechnology | Download | biotechnology |
05-29-2020 | BioSyent Inc. | TSX-V:RX | 1Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-29-2020 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | Additional TTI-622 Monotherapy Activity | Biotechnology | Download | biotechnology |
05-28-2020 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Takeaways from Virtual KOL Meeting | Biotechnology | Download | biotechnology |
05-27-2020 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | Discontinuing Coverage | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-26-2020 | Liminal BioSciences Inc. | TSX:LMNL | Coverage Transition | Biotechnology | Download | biotechnology |
05-26-2020 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Coverage Transition | Biotechnology | Download | biotechnology |
05-24-2020 | Greenbrook TMS Inc. | TSX:GTMS | Financing. 1Q-2020 Results. COVID Outlook | Healthcare Services | Download | healthcare-services |
05-19-2020 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-19-2020 | ESSA Pharma Inc. | NASDAQ:EPIX | Company Update – Value Inflection in Sight | Biotechnology | Download | biotechnology |
05-14-2020 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 1Q-2020 Financial Results | Healthcare Services | Download | healthcare-services |
05-12-2020 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 1Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-08-2020 | Cipher Pharmaceuticals Inc. | TSX:CPH | 1Q-2020 Financial Results; Upgrading to ACCUMULATE | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-07-2020 | HLS Therapeutics Inc. | TSX:HLS | 1Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-07-2020 | HLS Therapeutics Inc. | TSX:HLS | 1Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-05-2020 | Newtopia Inc. | TSX-V:NEWU | Research Initiation: Time for Something New | Digital Health | Download | digital-health |
04-23-2020 | Hamilton Thorne Ltd. | TSX-V:HTL | 4Q and FY-19 Results In Line; Near-term COVID Impact Uncertain, but HTL Remains a BUY for The Long Term | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
04-07-2020 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Not Ideal, But Outlook for P2 Trial Remains Positive | Biotechnology | Download | biotechnology |
04-05-2020 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Progress Despite COVID – Delays Priced In | Biotechnology | Download | biotechnology |
04-03-2020 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Spring Cleaning in Preparation for Summer. | Biotechnology | Download | biotechnology |
04-01-2020 | Knight Therapeutics Inc. | TSX:GUD | 4Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-31-2020 | HLS Therapeutics Inc. | TSX:HLS | Vascepa Patents Invalidated in the U.S | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-26-2020 | Cipher Pharmaceuticals Inc. | TSX:CPH | 4Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-25-2020 | Advanz Pharma Corp. | TSX:ADVZ | 4Q-2019 Results – Going out on a Strong Note. Discontinuing Coverage | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-20-2020 | HLS Therapeutics Inc. | TSX:HLS | 4Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-19-2020 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | COVID Correction: Phase 3 Completed Successfully | Biotechnology | Download | biotechnology |
03-19-2020 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | COVID Correction: Phase 3 Completed Successfully | Biotechnology | Download | biotechnology |
03-19-2020 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | COVID Correction: Phase 3 Completed Successfully | Biotechnology | Download | biotechnology |
03-19-2020 | BioSyent Inc. | TSX-V:RX | 4Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-19-2020 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | COVID Correction: 6 CNS Programs; 3 Good Partners; $225 MM Cash; $65 MM EV; Key Data this Year (Maybe) | Biotechnology | Download | biotechnology |
03-13-2020 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 4Q-2019 Financial Results | Healthcare Services | Download | healthcare-services |
03-09-2020 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-02-2020 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | FIX and Build | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-26-2020 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 4Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-20-2020 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 3Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-20-2020 | Hamilton Thorne Ltd. | TSX-V:HTL | Not Crowning, but Contractions 2 Minutes Apart | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
02-10-2020 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-06-2020 | The Therapeutic Window | | The Therapeutic Window | Sector Reports | Download | sector-reports |
01-30-2020 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | Closing of US$117 MM Public Offering | Biotechnology | Download | biotechnology |
01-29-2020 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Closing of $60 MM Public Offering | Biotechnology | Download | biotechnology |
01-29-2020 | HLS Therapeutics Inc. | TSX:HLS | Vascepa Launch and Pricing Update | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-25-2020 | MindBeacon Holdings Inc. | TSX:MBCN | Shining the Light on Digital Mental Health | Digital Health | Download | digital-health |
01-19-2020 | Cipher Pharmaceuticals Inc. | TSX:CPH | Discontinuing Coverage | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-14-2020 | HLS Therapeutics Inc. | TSX:HLS | Vascepa Competitors Fail in Clinical Trials | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-08-2020 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Not Reddy for Generic Vimovo Just Yet (V2) | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-08-2020 | Transition Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | Higher Doses Add New Responses Without Increasing Safety Risk | Biotechnology | Download | biotechnology |
01-06-2020 | HLS Therapeutics Inc. | TSX:HLS | Potential Extra Layers of IP Protection – Score 1 Today | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-06-2020 | HLS Therapeutics Inc. | TSX:HLS | Potential Extra Layers of IP Protection | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-16-2019 | HLS Therapeutics Inc. | TSX:HLS | New U.S. Vascepa Label Extends to Large Patient Population | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-13-2019 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | US$192 MM Financing Closed | Biotechnology | Download | biotechnology |
12-13-2019 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | Risky, but We Think Oversold | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-10-2019 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | Negative AdCom | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-09-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-09-2019 | HLS Therapeutics Inc. | TSX:HLS | Scenariopalooza | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-06-2019 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | Negative Briefing Documents | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-05-2019 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | AURORA Borealis! | Biotechnology | Download | biotechnology |
12-03-2019 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 2Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-03-2019 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | XEN901 License Agreement with Neurocrine | Biotechnology | Download | biotechnology |
12-02-2019 | Mimi’s Rock Corp. | TSX-V:MIMI | 3Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-22-2019 | Hamilton Thorne Ltd. | TSX-V:HTL | 3Q-2019 Financial Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
11-21-2019 | BioSyent Inc. | TSX-V:RX | 3Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-19-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-15-2019 | HLS Therapeutics Inc. | TSX:HLS | AdCom Votes Unanimously in Favor of sNDA Approval | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-15-2019 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | 3Q-2019 Financial Results. Prepping for AdCom | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-15-2019 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | 3Q-2019 Financial Results. Prepping for AdCom | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-14-2019 | Knight Therapeutics Inc. | TSX:GUD | 3Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-13-2019 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Gazyva Results Improved at 76 Weeks, But Voclosporin Opportunity Remains High | Biotechnology | Download | biotechnology |
11-13-2019 | HLS Therapeutics Inc. | TSX:HLS | Vascepa AdCom Briefing Documents | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-12-2019 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Not Reddy for Generic Vimovo Just Yet | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-11-2019 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 3Q-2019 Financial Results | Healthcare Services | Download | healthcare-services |
11-08-2019 | HLS Therapeutics Inc. | TSX:HLS | 3Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-08-2019 | Advanz Pharma Corp. | TSX:ADVZ | 3Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-08-2019 | Cipher Pharmaceuticals Inc. | TSX:CPH | 3Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-06-2019 | Greenbrook TMS NeuroHealth Inc. | TSX:GTMS | 3Q-2019 Financial Results | Healthcare Services | Download | healthcare-services |
11-01-2019 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 3Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-22-2019 | Knight Therapeutics Inc. | TSX:GUD | GUD Salsa – Back to the Business of Selling Drugs | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-21-2019 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Potentially Good News for U.S. VIMOVO. Hurdles Remain but Currently not in Mid/Long-term Forecasts – Upside Possible | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-18-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-04-2019 | HLS Therapeutics Inc. | TSX:HLS | KOLing HLS a Speculative BUY | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-01-2019 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Arigato Shionogi | Biotechnology | Download | biotechnology |
09-12-2019 | Greenbrook TMS NeuroHealth Inc. | TSX:GTMS | Acquisition Achieves Strategic Benefits – Financial Details Forthcoming | Healthcare Services | Download | healthcare-services |
09-10-2019 | Hamilton Thorne Ltd. | TSX-V:HTL | FDA Clearance of First Media Product (+ some new CE Marks) | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
09-09-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-09-2019 | CannTrust Holdings Inc. | CSE:TRST | Discontinuing Coverage: TRST | | Download | |
09-06-2019 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Share Consolidation and NASDAQ IPO | Biotechnology | Download | biotechnology |
09-06-2019 | Mimi’s Rock Corp. | TSX-V:MIMI | Strategic Acquisition Immediately Adds to EBITDA with Potential Cross-Selling Opportunities | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-30-2019 | Mimi’s Rock Corp. | TSX-V:MIMI | 2Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-28-2019 | ESSA Pharma Inc. | NASDAQ:EPIX | Balance Sheet Strengthened – Path to Potential Monetization Clear | Biotechnology | Download | biotechnology |
08-28-2019 | Hamilton Thorne Ltd. | TSX-V:HTL | 2Q-2019 Financial Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
08-23-2019 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 1Q-2020 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-15-2019 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 2Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-14-2019 | Hamilton Thorne Ltd. | TSX-V:HTL | Plane to See Immediate EBITDA Uptick and Future Potential Synergy | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
08-12-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-12-2019 | Cipher Pharmaceuticals Inc. | TSX:CPH | 2Q-2019 Results and Strategic Update | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-09-2019 | HLS Therapeutics Inc. | TSX:HLS | 2Q-2019 Financial Results and AdCom for Vascepa | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-09-2019 | Knight Therapeutics Inc. | TSX:GUD | 2Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-08-2019 | Greenbrook TMS NeuroHealth Inc. | TSX:GTMS | 2Q-2019 Financial Results | Healthcare Services | Download | healthcare-services |
08-08-2019 | Advanz Pharma Corp. | TSX:ADVZ | 2Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-01-2019 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Market Visibility Increasing. Ying/Yang of Competitors’ Results | Biotechnology | Download | biotechnology |
08-01-2019 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 2Q-2019 Financial Results; 2020 Proposed Fee Schedule | Healthcare Services | Download | healthcare-services |
07-30-2019 | Cipher Pharmaceuticals Inc. | TSX:CPH | 2Q-2019 Preliminary Results, Management Change. Rating Under Review | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-25-2019 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | Mark Late November and Christmas Eve on Your Calendars | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-24-2019 | CannTrust Holdings Inc. | CSE:TRST | Rating to Under Review | | Download | |
07-22-2019 | Mimi’s Rock Corp. | TSX-V:MIMI | Research Initiation: Online Brand Leader Expanding Channels | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-12-2019 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Valuation Update | Biotechnology | Download | biotechnology |
07-10-2019 | CannTrust Holdings Inc. | CSE:TRST | What were they thinking? | | Download | |
07-09-2019 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | 4Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-08-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-03-2019 | Medexus Pharmaceuticals Inc. | TSX-V:MDP | Research Initiation: Bigger and More Diverse | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-27-2019 | HLS Therapeutics Inc. | TSX:HLS | Update – Financing, Vascepa, Perseris | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-18-2019 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Corporate Update | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-18-2019 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Corporate Update | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-13-2019 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Filtering the Noise. Nearing a High Probability Phase 3 Readout | Biotechnology | Download | biotechnology |
06-10-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-06-2019 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | XEN901 Clinical Update | Biotechnology | Download | biotechnology |
05-24-2019 | Hamilton Thorne Ltd. | TSX-V:HTL | 1Q-2019 Financial Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
05-22-2019 | Greenbrook TMS NeuroHealth Inc. | TSX:GTMS | 1Q-2019 Results and Financing | Healthcare Services | Download | healthcare-services |
05-22-2019 | Novelion Therapeutics Inc. | NASDAQ:NVLN, NASDAQ: CMTA, OTC:ARLZQ | Discontinuing Coverage: NVLN; CMTA; ARLZQ | Biotechnology | Download | biotechnology |
05-16-2019 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Appeals Court Ruling Opens Door to Potential U.S. Vimovo Generics | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-15-2019 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 1Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-15-2019 | CannTrust Holdings Inc. | CSE:TRST | 1Q-2019 Financial Results | | Download | |
05-13-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-13-2019 | Advanz Pharma Corp. | TSX:ADVZ | 1Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-13-2019 | Cipher Pharmaceuticals Inc. | TSX:CPH | 1Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-10-2019 | HLS Therapeutics Inc. | TSX:HLS | 1Q-2019 Financial Results and New Product License | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-10-2019 | Knight Therapeutics Inc. | TSX:GUD | 1Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-09-2019 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | 1Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-03-2019 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 1Q-2019 Financial Results | Healthcare Services | Download | healthcare-services |
04-30-2019 | Hamilton Thorne Ltd. | TSX-V:HTL | 4Q-2018 Full Financial Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
04-24-2019 | Knight Therapeutics Inc. | TSX:GUD | Current Management, Board, Strategy the Better Choice for GUD Investors in our Opinion (With One Borrowed Idea) | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-10-2019 | Greenbrook TMS NeuroHealth Inc. | TSX:GTMS | Greenbrook Selected by Kaiser Permanente | Healthcare Services | Download | healthcare-services |
04-08-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-03-2019 | Prometic Life Sciences Inc. | TSX:PLI | Removing Target and Forecasts Pending Recapitalization | Biotechnology | Download | biotechnology |
04-01-2019 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 4Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-01-2019 | HLS Therapeutics Inc. | TSX:HLS | Priority Review for Vascepa | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-29-2019 | Greenbrook TMS NeuroHealth Inc. | TSX:GTMS | 4Q-2018 Financial Results | Healthcare Services | Download | healthcare-services |
03-22-2019 | HLS Therapeutics Inc. | TSX:HLS | 4Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-20-2019 | Cipher Pharmaceuticals Inc. | TSX:CPH | 4Q-2018 Financial Results. Attractive Valuation; Upgrading to BUY. | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-19-2019 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | COVID Correction; Almost Finished Transformational Phase 2 Trial | Biotechnology | Download | biotechnology |
03-18-2019 | Novelion Therapeutics Inc. | NASDAQ:NVLN | 4Q-2018 Financial Results | Biotechnology | Download | biotechnology |
03-15-2019 | Knight Therapeutics Inc. | TSX:GUD | 4Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-15-2019 | Advanz Pharma Corp. | TSX:ADVZ | 4Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-14-2019 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 4Q-2018 Financial Results | Healthcare Services | Download | healthcare-services |
03-14-2019 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | 4Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-12-2019 | Greenbrook TMS Inc. | TSX:GTMS | 4Q-2019 Financial Results | Healthcare Services | Download | healthcare-services |
03-11-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-26-2019 | Clementia Pharmaceuticals Inc. | NASDAQ:CMTA | $1 + $0.3 B Acquisition Agreement Announce | Biotechnology | Download | biotechnology |
02-25-2019 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Another Brick in Aurinia’s IP Wall May Add 10 Years of Additional Protection Vs Generics. Other Possible Value Lifts This Year | Biotechnology | Download | biotechnology |
02-25-2019 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | Financing Blows-up Share Count; Resets Near-Term Expectations; Highlights Missed Opportunities. But, We Don’t Think Investors Should Throw in the Towel | Biotechnology | Download | biotechnology |
02-19-2019 | Hamilton Thorne Ltd. | TSX-V:HTL | 4Q-2018 Preliminary Results – Attractive Industry and Business Strategy Beginning to Coalesce | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
02-19-2019 | Hamilton Thorne Ltd. | TSX-V:HTL | 4Q-2018 Preliminary Results – Attractive Industry and Business Strategy Beginning to Coalesce | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
02-15-2019 | ESSA Pharma Inc. | NASDAQ:EPIX | Search for Ideal Lead Nearing Completion – Long Methodical Process Should Pay-off Long Term, but Likely Necessitates Additional Cash Infusion | Biotechnology | Download | biotechnology |
02-07-2019 | Medicenna Therapeutics Corp. | NASDAQ:MDNA; TSX:MDNA | Research Initiation: Superkine’d | Biotechnology | Download | biotechnology |
01-24-2019 | The Therapeutic Window | | The Therapeutic Window | Sector Reports | Download | sector-reports |
01-23-2019 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Buy the Eye | Biotechnology | Download | biotechnology |
01-14-2019 | Knight Therapeutics Inc. | TSX:GUD | GUD Early Move into Oncology – NERLYNX License | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-14-2019 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-31-2018 | Nuvo Pharmaceuticals Inc. | TSX:NRI | NEWVO – Aralez Asset Acquisition Closed | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-17-2018 | Clementia Pharmaceuticals Inc. | NASDAQ:CMTA | High Value, High Probability Orphan Candidate | Biotechnology | Download | biotechnology |
12-10-2018 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-04-2018 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | XEN1101 and XEN901 Clinical Updates | Biotechnology | Download | biotechnology |
11-22-2018 | BioSyent Inc. | TSX-V:RX | 3Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-21-2018 | Hamilton Thorne Ltd. | TSX-V:HTL | 3Q-2018 Financial Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
11-20-2018 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | BLU-5937 Phase 1 – Solid Step Toward Potential Best-in-Class | Biotechnology | Download | biotechnology |
11-16-2018 | HLS Therapeutics Inc. | TSX-V:HLS | 3Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-16-2018 | CannTrust Holdings Inc. | CSE:TRST | 3Q-2018 Financial Results | | Download | |
11-14-2018 | Greenbrook TMS NeuroHealth Inc. | TSX:GTMS | 3Q-2018 Financial Results | Healthcare Services | Download | healthcare-services |
11-13-2018 | Novelion Therapeutics Inc. | NASDAQ:NVLN | 3Q-2018 Financial Results; Short Fuse Bridge Financing | Biotechnology | Download | biotechnology |
11-12-2018 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-11-2018 | HLS Therapeutics Inc. | TSX-V:HLS | REDUCE-IT Increases It | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-09-2018 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 3Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-09-2018 | Knight Therapeutics Inc. | TSX:GUD | 3Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-08-2018 | Cipher Pharmaceuticals Inc. | TSX:CPH | 3Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-08-2018 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | 3Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-02-2018 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 3Q-2018 Financial Results | Healthcare Services | Download | healthcare-services |
10-25-2018 | HLS Therapeutics Inc. | TSX-V:HLS | Potential Clozaril Competitor Fails | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-17-2018 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | GDC-0310 Terminated by Genentech/Roche | Biotechnology | Download | biotechnology |
10-17-2018 | Arbutus Biopharma Corporation | NASDAQ: ABUS | Discontinuing Coverage | Biotechnology | Download | biotechnology |
10-15-2018 | HLS Therapeutics Inc. | TSX-V:HLS | KOL Call Highlights – The Good, The Uncertain, and What to Look For at AHA | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-10-2018 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-09-2018 | HLS Therapeutics Inc. | TSX-V:HLS | Investor Invitation: Bloom Burton Vascepa Call With a Dyslipidemia KOL | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-03-2018 | Greenbrook TMS NeuroHealth Inc. | TSX:GTMS | Research Initiation: Flowing into a Greenfield Opportunity | Healthcare Services | Download | healthcare-services |
10-03-2018 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | TTI-621-01 and -02 Trial Updates | Biotechnology | Download | biotechnology |
09-27-2018 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | AURORA Enrollment Completed | Biotechnology | Download | biotechnology |
09-25-2018 | HLS Therapeutics Inc. | TSX-V:HLS | Better Bigger Vascepa | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-24-2018 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Definitive Agreement Signed for Acquisition of Aralez Assets | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-19-2018 | Cipher Pharmaceuticals Inc. | TSX:CPH | Derm Pipeline Build Continues with MOB-015. Model Update | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-11-2018 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Restructuring and Share Consolidation Complete | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-10-2018 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-07-2018 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Innovative Pipeline Build Continues with XEN496 | Biotechnology | Download | biotechnology |
09-06-2018 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | SPECTRUM Increases Odds of Brinavess Approval in U.S | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-30-2018 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Additional XEN1101 TMS Data | Biotechnology | Download | biotechnology |
08-26-2018 | BioSyent Inc. | TSX-V:RX | 2Q-2019 Results. Upgrading to BUY on Valuation | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-23-2018 | BioSyent Inc. | TSX-V:RX | 2Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-23-2018 | Hamilton Thorne Ltd. | TSX-V:HTL | 2Q-2018 Financial Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
08-16-2018 | HLS Therapeutics Inc. | TSX-V:HLS | 2Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-15-2018 | CannTrust Holdings Inc. | CSE:TRST | 2Q-2018 Financial Results | | Download | |
08-15-2018 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | 2Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-13-2018 | Nuvo Pharmaceuticals Inc. | TSX:NRI | LOI Signed for Potentially Transformative Deal. Positive 2Q2018 Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-13-2018 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-13-2018 | Cipher Pharmaceuticals Inc. | TSX:CPH | 2Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-10-2018 | Knight Therapeutics Inc. | TSX:GUD | 2Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-10-2018 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | End of the Line. Likely No (or Nominal) Value for Equity | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-08-2018 | Novelion Therapeutics Inc. | NASDAQ:NVLN | 2Q-2018 Financial Results | Biotechnology | Download | biotechnology |
07-31-2018 | Cipher Pharmaceuticals Inc. | TSX:CPH | Amended Absorica Distribution Agreement | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-20-2018 | Hamilton Thorne Ltd. | TSX-V:HTL | ZANDAIR Acquisition | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
07-17-2018 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | ATM Share Sales Strengthen Balance Sheet; Reduce Risk | Biotechnology | Download | biotechnology |
07-09-2018 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | TRIL Update, Forty Seven ASCO Results and IPO | Biotechnology | Download | biotechnology |
07-06-2018 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Sexy P2X-i (Update) – Clinical Milestones Coming into Focus | Biotechnology | Download | biotechnology |
06-29-2018 | CannTrust Holdings Inc. | CSE:TRST | Post-financing Update. Days Ahead Will Separate Boys from Men | | Download | |
06-21-2018 | Knight Therapeutics Inc. | TSX:GUD | Updating Sum-of-Parts Valuation; Pondering Strategy | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-12-2018 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-12-2018 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | U.S. Regulatory Update for BRINAVESS (IV vernakalant) | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-04-2018 | Novelion Therapeutics Inc. | NASDAQ:NVLN | Positive CHMP Opinion for MYALEPTA – Two Indications | Biotechnology | Download | biotechnology |
05-31-2018 | BioSyent Inc. | TSX-V:RX | 1Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-30-2018 | BioSyent Inc. | TSX-V:RX | 1Q-2019 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-25-2018 | Hamilton Thorne Ltd. | TSX-V:HTL | 1Q-2018 Financial Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
05-17-2018 | HLS Therapeutics Inc. | TSX-V:HLS | 1Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-17-2018 | Correvio Pharma Corp. | NASDAQ:CRME, TSX:COM | 1Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-15-2018 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Positive Safety and PD – XEN1101, XEN901 Interim Phase 1 Data | Biotechnology | Download | biotechnology |
05-11-2018 | Novelion Therapeutics Inc. | NASDAQ:NVLN | 1Q-2018 Financial Results | Biotechnology | Download | biotechnology |
05-11-2018 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 1Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-11-2018 | Knight Therapeutics Inc. | TSX:GUD | 1Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-11-2018 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-11-2018 | Cipher Pharmaceuticals Inc. | TSX:CPH | 1Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-09-2018 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | 1Q-2018 Results: Improving Performance not Enough to Support Ongoing Zontivity Sales and Marketing; Prompts Major Restructure | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-08-2018 | Novelion Therapeutics Inc. | NASDAQ:NVLN | 1Q-2018 Financial Results Preview | Biotechnology | Download | biotechnology |
04-30-2018 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | United Therapeutics to Acquire SteadyMed | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-30-2018 | Prometic Life Sciences Inc. | TSX:PLI | Positive Interim IVIG Data | Biotechnology | Download | biotechnology |
04-26-2018 | Hamilton Thorne Ltd. | TSX-V:HTL | 4Q-2017 Financial Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
04-24-2018 | HLS Therapeutics Inc. | TSX-V:HLS | Absorica update | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-24-2018 | Cipher Pharmaceuticals Inc. | TSX:CPH | Preliminary 1Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-23-2018 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Estimates Revision | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-09-2018 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-06-2018 | Hamilton Thorne Ltd. | TSX-V:HTL | Hooking-up to Make Babies | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
04-05-2018 | CannTrust Holdings Inc. | CSE:TRST | 4Q-2017 Results | | Download | |
04-02-2018 | HLS Therapeutics Inc. | TSX-V:HLS | 4Q-2017 Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-29-2018 | Prometic Life Sciences Inc. | TSX:PLI | 4Q-2017 Financial Results | Biotechnology | Download | biotechnology |
03-29-2018 | CannTrust Holdings Inc. | CSE:TRST | 4Q-2018 Financial Results | | Download | |
03-26-2018 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 4Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-22-2018 | BioSyent Inc. | TSX-V:RX | 4Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-21-2018 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | WIN | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-21-2018 | BioSyent Inc. | TSX-V:RX | 4Q-2018 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-21-2018 | Cipher Pharmaceuticals Inc. | TSX:CPH | Win | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-19-2018 | Novelion Therapeutics Inc. | NASDAQ:NVLN | 4Q-2017 Financial Results | Biotechnology | Download | biotechnology |
03-16-2018 | Knight Therapeutics Inc. | TSX:GUD | 4Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-15-2018 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 4Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-14-2018 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | 4Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-12-2018 | HLS Therapeutics Inc. | TSX-V:HLS | Research Initiation – HLS’ Belles | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-12-2018 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-09-2018 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | 4Q-2017 Financial Results and New Migraine Program | Biotechnology | Download | biotechnology |
03-01-2018 | Cipher Pharmaceuticals Inc. | TSX:CPH | 4Q-2017 Financial Results. Trulance Acquisition | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-16-2018 | CannTrust Holdings Inc. | CSE:TRST | Thriving in the Depths of Winter – Well-Positioned for Rec and International | | Download | |
02-14-2018 | Hamilton Thorne Ltd. | TSX-V:HTL | 4Q-2017 Preliminary Revenues and Adjusted EBITDA | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
02-12-2018 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-01-2018 | Novelion Therapeutics Inc. | NASDAQ:NVLN | One Major Overhang Resolved Favorably: Judge’s Sentencing | Biotechnology | Download | biotechnology |
01-27-2018 | The Therapeutic Window | | The Therapeutic Window | Sector Reports | Download | sector-reports |
01-18-2018 | ESSA Pharma Inc. | NASDAQ:EPIX | Cashed-up + Great Target + Lessons Learned = Ideal Reset SPEC BUY | Biotechnology | Download | biotechnology |
01-16-2018 | Nuvo Pharmaceuticals Inc. | TSX:NRI | U.S. Licensing Agreement Extends Rights to Resultz Globally | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-03-2018 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Resultz – Small But Strategic (and Impactful on 11.6 MM Share Base) | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-01-2018 | Top Ideas | | 2018 Top Ideas; Healthcare Sector Review/Preview | Sector Reports | Download | sector-reports |
12-12-2017 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | ASH 2017 Mixed for TRIL, But a Potential Path Emerging | Biotechnology | Download | biotechnology |
12-11-2017 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-24-2017 | CannTrust Holdings Inc. | CSE:TRST | 3Q-2017 Financial Results | | Download | |
11-23-2017 | Hamilton Thorne Ltd. | TSX-V:HTL | 3Q-2017 Financial Results | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
11-23-2017 | Prometic Life Sciences Inc. | TSX:PLI | IVIG Interim 6-Month Update | Biotechnology | Download | biotechnology |
11-16-2017 | BioSyent Inc. | TSX-V:RX | 3Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-15-2017 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Specialty Pharmaceutical | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-15-2017 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 3Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-13-2017 | Novelion Therapeutics Inc. | NASDAQ:NVLN | Update on the DOJ Settlement | Biotechnology | Download | biotechnology |
11-13-2017 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-13-2017 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | SITC Posters: Incremental Efficacy/PD Color; No New Safety Red Flags – More Details Expected at ASH | Biotechnology | Download | biotechnology |
11-10-2017 | Novelion Therapeutics Inc. | NASDAQ:NVLN | Weak 3Q-2017 Results; Leadership Change | Biotechnology | Download | biotechnology |
11-10-2017 | Knight Therapeutics Inc. | TSX:GUD | 3Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-10-2017 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | 3Q-2017 Financial Results. The Ship is Turning | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-08-2017 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | GDC-0310 Shoe Drops (almost completely) | Biotechnology | Download | biotechnology |
11-08-2017 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TRIL | SITC Abstracts | Biotechnology | Download | biotechnology |
11-06-2017 | Cipher Pharmaceuticals Inc. | TSX:CPH | 3Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-03-2017 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 3Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-02-2017 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | TRIL Rebounding from Last Year’s ASH Kicking | Biotechnology | Download | biotechnology |
10-27-2017 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | COMPASS Likely to Impact Zontivity Path to Success | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-25-2017 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Potential New Indications for Voclosporin | Biotechnology | Download | biotechnology |
10-24-2017 | Hamilton Thorne Ltd. | TSX-V:HTL | Research Initiation: Be My Baby | Healthcare Equipment and Supplies | Download | healthcare-equipment-supplies |
10-18-2017 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | A Small Positive Step on the Path to ASH 2017 | Biotechnology | Download | biotechnology |
10-16-2017 | Prometic Life Sciences Inc. | TSX:PLI | Better Late than Never | Biotechnology | Download | biotechnology |
10-13-2017 | CannTrust Holdings Inc. | CSE:TRST | CannTrust Update – Metrics and Milestones | | Download | |
10-12-2017 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-29-2017 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Sexy P2X-i | Biotechnology | Download | biotechnology |
09-26-2017 | Arbutus Biopharma Corporation | NASDAQ: ABUS | Cohort 4 (Bi-Weekly) Data from the ARB-1467 Phase 2 Trial | Biotechnology | Download | biotechnology |
09-26-2017 | Prometic Life Sciences Inc. | TSX:PLI | Probability of a PRV | Biotechnology | Download | biotechnology |
09-20-2017 | Arbutus Biopharma Corporation | NASDAQ: ABUS | Positive Phase 3 Results for Patisiran – Gas for the BUS! | Biotechnology | Download | biotechnology |
09-20-2017 | Prometic Life Sciences Inc. | TSX:PLI | Another Alström Syndrome Interim | Biotechnology | Download | biotechnology |
09-18-2017 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | BLU-5937 Preclinical Head-to-Head Results vs Merck Comp Leave a Good Taste in Our Mouth | Biotechnology | Download | biotechnology |
09-13-2017 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Zevtera License Deal | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-12-2017 | ESSA Pharma Inc. | NASDAQ:EPIX | EPI-506 Phase 1 Provides Some POC But PK Hurdles Too High | Biotechnology | Download | biotechnology |
09-12-2017 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-07-2017 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | DELIVER Strategy Update | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-01-2017 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | SteadyMed Receives RTF | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-30-2017 | Prometic Life Sciences Inc. | TSX:PLI | Rare Pediatric Disease Designation for Plasminogen | Biotechnology | Download | biotechnology |
08-29-2017 | CannTrust Holdings Inc. | CSE:TRST | 2Q-2017 Financial Results | | Download | |
08-18-2017 | CannTrust Holdings Inc. | CSE:TRST | Strong Business Fundamentals, Nice Valuation | | Download | |
08-17-2017 | BioSyent Inc. | TSX-V:RX | 2Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-16-2017 | Prometic Life Sciences Inc. | TSX:PLI | 2Q-2017 Financial Results | Biotechnology | Download | biotechnology |
08-14-2017 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 2Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-14-2017 | Cipher Pharmaceuticals Inc. | TSX:CPH | 2Q-2017 Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-11-2017 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 2Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-11-2017 | Knight Therapeutics Inc. | TSX:GUD | 2Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-10-2017 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | 2Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-09-2017 | Novelion Therapeutics Inc. | NASDAQ:NVLN | Novelion Therapeutics Inc. (NASDAQ:NVLN; US$9.22) | Biotechnology | Download | biotechnology |
08-09-2017 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 2Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-04-2017 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
07-11-2017 | Script Trends | | Script Trends | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-30-2017 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | BUY Thesis Starting to Play-out | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-28-2017 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Second Failed Phase 2 – Darkest Before the Dawn? | Biotechnology | Download | biotechnology |
06-19-2017 | Novelion Therapeutics Inc. | NASDAQ:NVLN | Research Initiation: Good Merger for Both Sides | Biotechnology | Download | biotechnology |
06-06-2017 | ESSA Pharma Inc. | NASDAQ:EPIX | 6th Cohort Data Adds Uncertainty | Biotechnology | Download | biotechnology |
05-26-2017 | BioSyent Inc. | TSX-V:RX | 1Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-18-2017 | ESSA Pharma Inc. | NASDAQ:EPIX | First Hints of EPI-506 Efficacy – More Data at ASCO | Biotechnology | Download | biotechnology |
05-16-2017 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 1Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-15-2017 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Near-Term Generic Risk Gone, but EU Opportunity Likely Gone Too | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-12-2017 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 1Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-12-2017 | Knight Therapeutics Inc. | TSX:GUD | 1Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-12-2017 | Cipher Pharmaceuticals Inc. | TSX:CPH | 1Q-2017 Results. Confluence of Positive Factors. Upgrading to BUY | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-11-2017 | Merus Labs International Inc. | TSX:MSL; NASDAQ:MSLI | MSL to be Acquired for C$1.65 per Share | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-11-2017 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 1Q-2017 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-10-2017 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | 1Q-2017 Results: Additional Steps to Reduce Costs Welcome; Success or Failure Still Hinges on Zontivity | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-09-2017 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Horizon Sneezes – Nuvo Likely to Catch a Cold | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-27-2017 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | The Zen of XEN1101 | Biotechnology | Download | biotechnology |
04-10-2017 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | Upgrading ARLZ to BUY (Speculative) Following Sharp Sell-Off – Zontivity the Key Reason to Own at this Level | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-07-2017 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | No Extra Hurdles for International Approval of Voclosporin | Biotechnology | Download | biotechnology |
04-04-2017 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | Early Phase 1b Highlights: First Complete Remission With TTI-621 Monotherapy; Signs of Efficacy in Combo With Rituxan | Biotechnology | Download | biotechnology |
04-04-2017 | Cipher Pharmaceuticals Inc. | TSX:CPH | Amendment to Athyrium debt facility | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-03-2017 | Prometic Life Sciences Inc. | TSX:PLI | 4Q-2016 Financial Results | Biotechnology | Download | biotechnology |
03-31-2017 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Flash: SteadyMed Favorable Ruling in Inter Partes Review | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-27-2017 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | XEN801 Fails Phase 2a Acne Trial | Biotechnology | Download | biotechnology |
03-16-2017 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 4Q-2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-16-2017 | BioSyent Inc. | TSX-V:RX | 4Q-2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-14-2017 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | 4Q-2016 Financial Results – Toprol Joins Yosprala as a Concern. Zoning in on Zontivity | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-08-2017 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 4Q-2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-03-2017 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 4Q-2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-03-2017 | Cipher Pharmaceuticals Inc. | TSX:CPH | 4Q-16 Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-02-2017 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | AURA-LV Results Even Better at 48 Weeks | Biotechnology | Download | biotechnology |
03-01-2017 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Back in the Saddle | Biotechnology | Download | biotechnology |
02-16-2017 | Merus Labs International Inc. | TSX:MSL; NASDAQ:MSLI | FY1Q-17 Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-16-2017 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | PK/PD Boosts Possibility of Monotherapy Activity | Biotechnology | Download | biotechnology |
02-13-2017 | Merus Labs International Inc. | TSX:MSL; NASDAQ:MSLI | Expected Product Erosions, Balance Sheet Weigh | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-13-2017 | BioSyent Inc. | TSX-V:RX | Strong Record of Growth/Profitability Reflected in Valuation | Biotechnology | Download | biotechnology |
02-13-2017 | Cipher Pharmaceuticals Inc. | TSX:CPH | U.S. Stumble Likely Priced-in | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
01-20-2017 | Prometic Life Sciences Inc. | TSX:PLI | FDA Priority Review Voucher (PRV) for Plasminogen? | Biotechnology | Download | biotechnology |
01-09-2017 | Arbutus Biopharma Corporation | NASDAQ: ABUS | Rating Upgrade – Get on the BUS! | Biotechnology | Download | biotechnology |
01-05-2017 | Prometic Life Sciences Inc. | TSX:PLI | ProMetic Buys Back Plasminogen Rights | Biotechnology | Download | biotechnology |
01-04-2017 | Top Ideas | | 2017 Top Ideas; Healthcare Sector Review/Preview | Sector Reports | Download | sector-reports |
12-22-2016 | Xenon Pharmaceuticals Inc. | NASDAQ:XENE | Research Initiation | Biotechnology | Download | biotechnology |
12-19-2016 | Prometic Life Sciences Inc. | TSX:PLI | BLA Filing for Plasminogen | Biotechnology | Download | biotechnology |
12-15-2016 | Knight Therapeutics Inc. | TSX:GUD | License Agreement for Movantik in Canada and Israel | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-15-2016 | Knight Therapeutics Inc. | TSX:GUD | License Agreement for Movantik in Canada and Israel | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-14-2016 | Arbutus Biopharma Corporation | NASDAQ: ABUS | Additional Data from the ARB-1467 Phase 2 Trial | Biotechnology | Download | biotechnology |
12-05-2016 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | TTI-621 Phase 1a Results | Biotechnology | Download | biotechnology |
11-30-2016 | Prometic Life Sciences Inc. | TSX:PLI | Missing Patients and PBI-4050 Structure | Biotechnology | Download | biotechnology |
11-22-2016 | Prometic Life Sciences Inc. | TSX:PLI | Analyst Day Recap. Valuation High and Balance Sheet Lite Ahead of Next Expected, Riskier Steps, in Our Opinion | Biotechnology | Download | biotechnology |
11-17-2016 | Prometic Life Sciences Inc. | TSX:PLI | Early IPF Results – Look Similar to Early Esbriet Results. Catch-22? | Biotechnology | Download | biotechnology |
11-15-2016 | Prometic Life Sciences Inc. | TSX:PLI | 3Q-2016 Financial Results | Biotechnology | Download | biotechnology |
11-14-2016 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | Forty Seven’s Hu5F9-G4 Continues to Underwhelm as Monotherapy. Science, Risk/Reward Still Favor TRIL – Spec BUY if TRIL Sells | Biotechnology | Download | biotechnology |
11-14-2016 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | Forty Seven’s Hu5F9-G4 Continues to Underwhelm as Monotherapy. Science, Risk/Reward Still Favor TRIL – Spec BUY if TRIL Sells | Biotechnology | Download | biotechnology |
11-11-2016 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 3Q-2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-10-2016 | Knight Therapeutics Inc. | TSX:GUD | 3Q-2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-09-2016 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 3Q-2016 Financial Results. XYDALBA Soon Launching | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-08-2016 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | 3Q Beats Estimates. YOSPRALA Launch; Macro Factors | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-07-2016 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 3Q-2016 Financial Results. Throwing in the Towel | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-04-2016 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | When 1 is Better than 2 | Biotechnology | Download | biotechnology |
11-04-2016 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | Tomâto-Tomäto. Toxicity-Activity? We Think Buying Opportunity | Biotechnology | Download | biotechnology |
11-02-2016 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 3Q-2016 Preview. Scripts Down; Markman Decision | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-27-2016 | Prometic Life Sciences Inc. | TSX:PLI | Plasminogen Meets Endpoints in Pivotal Phase2/3 Trial | Biotechnology | Download | biotechnology |
10-26-2016 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | CMA Investigating CXRX Drug Prices. 2nd Reading of Health Service Medical Supplies (Costs) Bill Faces Little Objection | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-21-2016 | Prometic Life Sciences Inc. | TSX:PLI | More Data in Metabolic Syndrome and Type 2 Diabetes | Biotechnology | Download | biotechnology |
10-13-2016 | Prometic Life Sciences Inc. | TSX:PLI | Early PBI-4050 Clinical Results in Alström Syndrome | Biotechnology | Download | biotechnology |
10-07-2016 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Hail Mary | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-06-2016 | Arbutus Biopharma Corporation | NASDAQ: ABUS | Alnylam Terminates Revusiran. Good? Bad? For ABUS – We Think Good | Biotechnology | Download | biotechnology |
10-06-2016 | Prometic Life Sciences Inc. | TSX:PLI | Good? Bad? Inconclusive? Upcoming Clinical Results | Biotechnology | Download | biotechnology |
10-05-2016 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | Growing Into Its Market Cap | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-03-2016 | Arbutus Biopharma Corporation | NASDAQ: ABUS | Arbutus Reports Interim Data for ARB-1467 | Biotechnology | Download | biotechnology |
10-03-2016 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Additional AURA-LV Details | Biotechnology | Download | biotechnology |
09-19-2016 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Proposed UK Health Service Medical Supplies (Costs) Bill Adds Substantial Risk to Concordia | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-16-2016 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | YOSPRALA Granted FDA Approval | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-08-2016 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | ZONTIVITY Adds to Growing Cardiovascular Business | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-25-2016 | Prometic Life Sciences Inc. | TSX:PLI | Acquisition of Telesta | Biotechnology | Download | biotechnology |
08-18-2016 | Prometic Life Sciences Inc. | TSX:PLI | Research Initiation. Fully Valued for Risk/Reward | Biotechnology | Download | biotechnology |
08-16-2016 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | AURA-LV – Complex Patients; Complex Trial; Complex Topline Results. Encouraging with Wrinkles | Biotechnology | Download | biotechnology |
08-12-2016 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 2Q-2016 Financial Results. Soon to be a Unicycle | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-11-2016 | Nuvo Pharmaceuticals Inc. | TSX:NRI | 2Q- 2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-11-2016 | Knight Therapeutics Inc. | TSX:GUD | 2Q-2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-10-2016 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Cardiome – Second Quarter 2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-09-2016 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | 2Q Beats Estimates | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-08-2016 | Arbutus Biopharma Corporation | NASDAQ: ABUS | Arbutus Trims Pipeline; Provides Corporate Update | Biotechnology | Download | biotechnology |
07-26-2016 | ESSA Pharma Inc. | NASDAQ:EPIX | Competitor Fails in Phase 3 | Biotechnology | Download | biotechnology |
07-26-2016 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Punishing Financing for Current Shareholders | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-24-2016 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Brexit Vote Adds Headwinds and Uncertainty | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-20-2016 | Nuvo Pharmaceuticals Inc. | TSX:NRI | Initiation – Flipping the Switch to Positive Cash Flow | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-20-2016 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Kiacta Fails in Phase 3 AA Amyloidosis Study | Biotechnology | Download | biotechnology |
06-08-2016 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | Competitor’s “Anemic” Data Increases TRIL Risk/Reward | Biotechnology | Download | biotechnology |
06-02-2016 | Knight Therapeutics Inc. | TSX:GUD | 1Q-2016 Financial Results and Subsequent Events | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-02-2016 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | CRH Acquires Majority Stake in AGAA | Healthcare Services | Download | healthcare-services |
05-19-2016 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | ASCO Abstracts – No CD47 Fireworks, But Class-Leading Potential for TTI-621 Gains a Bit More Support | Biotechnology | Download | biotechnology |
05-16-2016 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Additional AURION Results | Biotechnology | Download | biotechnology |
05-16-2016 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 1Q-2016 Revenues, EBITDA Beat. Some Gives and Takes | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-16-2016 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Cardiome – First Quarter 2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-11-2016 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | 1Q Below Estimates – Near-term Events Expected to Drive Stock | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-09-2016 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | XYDALBA Moves Cardiome to the Next Level | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-29-2016 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | Q1-2016 Results – Strong Top Line; Lower Margins | Healthcare Services | Download | healthcare-services |
04-27-2016 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Valuing Potential Outcomes | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-26-2016 | Knight Therapeutics Inc. | TSX:GUD | Knight Receives Health Canada NOD for Atryn; Signs Neuragen Commercial Partner for the Middle East | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-26-2016 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | Health Canada Approves BLEXTEN | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-22-2016 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Much Ado About Something? PE Interest Makes Sense to Us | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-15-2016 | Knight Therapeutics Inc. | TSX:GUD | A Deeper Dive | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-28-2016 | Knight Therapeutics Inc. | TSX-V:GUD | Fourth Quarter 2015 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-28-2016 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 4Q-2015 Results Mixed. Value Opportunity Intact | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-28-2016 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | Publishing Updated Forecasts | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-17-2016 | Knight Therapeutics Inc. | TSX:GUD | 4Q-2016 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-10-2016 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 4Q-2015 Light, But Relevance Low | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-09-2016 | Aralez Pharmaceuticals Inc. | NASDAQ:ARLZ; TSX:ARZ | Birth of a Diversified, Well-Capitalized Specialty Pharma Company With Multiple Near-Term Inflection Points | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-26-2016 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | Generally In-Line 4Q Caps a Transformative 2015 | Healthcare Services | Download | healthcare-services |
02-13-2016 | Industry Overview | | Introduction | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-08-2016 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Early AURION Results Potentially Positive for AURA-LV | Biotechnology | Download | biotechnology |
02-03-2016 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | First Patient Dosed | Biotechnology | Download | biotechnology |
01-28-2016 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Orphan Drug Application Filed for Oral Vernkalant | Biotechnology | Download | biotechnology |
01-28-2016 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | Buys Drug Discovery Platform – Potential to Expand Immuno-oncology Portfolio; Monetize Other Programs | Biotechnology | Download | biotechnology |
01-25-2016 | Bellus Health Inc. | NASDAQ:BLU; TSX: BLU | Another Important Countdown Begins | Biotechnology | Download | biotechnology |
01-22-2016 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Countdown Begins | Biotechnology | Download | biotechnology |
01-19-2016 | ESSA Pharma Inc. | NASDAQ:EPIX | Research Initiation – Validated Drug Target, Funded to a Potential Near-Term $1 B Liquidity Event | Biotechnology | Download | biotechnology |
01-04-2016 | Top Ideas | | 2016 Top Ideas: CRH and Basket of Small Cap Biotechs | Sector Reports | Download | sector-reports |
12-14-2015 | CRH Medical Corp. | TSX:CRH, NASDAQ:CRHM | Bringing Home the Macon | Healthcare Services | Download | healthcare-services |
12-08-2015 | CRH Medical Corp. | TSX:CRH, NASDAQ:CRHM | Georgia on My Mind – GAA Visit Strengthens BUY Thesis | Healthcare Services | Download | healthcare-services |
11-25-2015 | CRH Medical Corp. | TSX:CRH, NASDAQ:CRHM | CRH Secures New Debt With Lower Interest Rate | Healthcare Services | Download | healthcare-services |
11-12-2015 | Knight Therapeutics Inc. | TSX-V:GUD | Third Quarter 2015 Financial Results | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-12-2015 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 3Q-2015 Financial Results. Our Initial Take | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
11-09-2015 | Canadian Healthcare Sector | | Canadian Healthcare Sector | Sector Reports | Download | sector-reports |
11-09-2015 | CRH Medical Corp. | TSX:CRH, NASDAQ:CRHM | CMS Final Rule – Anesthesia Reimbursement Unchanged in 2016. Looking Ahead | Healthcare Services | Download | healthcare-services |
10-30-2015 | CRH Medical Corp. | TSX:CRH, NASDAQ:CRHM | Third Quarter 2015 Results | Healthcare Services | Download | healthcare-services |
10-27-2015 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Preliminary 2016 Guidance | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-12-2015 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Concordia Discloses Maximum Debt Rate of 7.25% | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-09-2015 | Arbutus Biopharma Corporation | NASDAQ:ABUS | Don’t Write-off the BUS | Biotechnology | Download | biotechnology |
10-07-2015 | Knight Therapeutics Inc. | TSX-V:GUD | Advaxis Lead Program Placed on Clinical Hold | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
10-05-2015 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | Reducing Target Price Based on Lower Comps, but Increasing Rating to BUY Due to Stock Pullback | Biotechnology | Download | biotechnology |
09-28-2015 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Unfortunate Timing | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-11-2015 | CRH Medical Corp. | TSX:CRH, NASDAQ:CRHM | CRH Keeps it Rollin’ with Second Transaction in a Month | Healthcare Services | Download | healthcare-services |
09-09-2015 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | Concordia Gains International Footprint with AMCo Buy | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
09-01-2015 | Knight Therapeutics Inc. | TSX:GUD | Big Step in Molding Knight’s Future | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-26-2015 | Knight Therapeutics Inc. | TSX-V:GUD | Pre-Phase 3 Cancer Immunotherapy Licensing Deal | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-19-2015 | CRH Medical Corp. | TSX:CRH, | Incremental Acquisition Bumps Target Price to $5.90 | Healthcare Services | Download | healthcare-services |
08-17-2015 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 2Q-2015 Financials In-Line. M&A Remains Key Driver | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-13-2015 | Knight Therapeutics Inc. | TSX-V:GUD | 2Q Review – Good Income from Investing/Lending Strategy; Pipeline Build Continues | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
08-05-2015 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 2Q-2015 Results | Biotechnology | Download | biotechnology |
07-30-2015 | CRH Medical Corp. | TSX:CRH | 2Q-2015 Results | Healthcare Services | Download | healthcare-services |
07-23-2015 | Knight Therapeutics Inc. | TSX-V:GUD | It’s Been a Busy Knight (including company’s first fundsourced product deal) | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
06-23-2015 | Tekmira Pharmaceuticals Corporation | NASDAQ:TKMR | TKM-Ebola-Guinea Trial Fails | Biotechnology | Download | biotechnology |
06-11-2015 | Trillium Therapeutics Inc. | NASDAQ:TRIL, TSX:TR | Increasing Target Price but Reducing Rating Due to Stock Appreciation | Biotechnology | Download | biotechnology |
06-08-2015 | CRH Medical Corp. | TSX:CRH | Research Initiation – Attractive Healthcare Roll-up Opportunity | Healthcare Services | Download | healthcare-services |
05-27-2015 | Concordia International Corp. | TSX: CXR | Management, Board Changes. Proposed FTC Settlement Negotiated | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-26-2015 | Concordia International Corp. | TSX: CXR | Plaquenil Market Undergoing Major Shift – Concordia’s Authorized Generic a Leading Beneficiary | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-22-2015 | Tribute Pharmaceuticals Canada Inc. | TSX-V: TRX | U.S. Expansion Initiated with Small Acquisition | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-19-2015 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 1Q-2015 Below Estimates on Donnatal De-Stocking; SHD | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-15-2015 | Knight Therapeutics Inc. | TSX-V:GUD | Cheap Product Deals Remain Elusive for Now; 1Q-2015 Financial Results Show Upside to Loan Strategy | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-13-2015 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Mixed 1Q-2015 Results; New Product Licensed; Waiting on FDA | Biotechnology | Download | biotechnology |
05-13-2015 | Tribute Pharmaceuticals Canada Inc. | TSX-V: TRX | 1Q-2015 Financial Results In Line – Growth Continues | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
05-12-2015 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 1Q-2015 Financial Results Preview | Biotechnology | Download | biotechnology |
04-27-2015 | Concordia International Corp. | NASDAQ: CXRX, TSX: CXR | 1Q-2015 Financial Results Preview | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
04-09-2015 | Tekmira Pharmaceuticals Corporation | NASDAQ:TKMR | Research Initiation – Many Shots on Goal | Biotechnology | Download | biotechnology |
03-23-2015 | Concordia International Corp. | TSX: CXR | 4Q-2014 Achieves Top End of Recent Guidance | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-20-2015 | Knight Therapeutics Inc. | TSX-V:GUD | 4Q-2014 In Line | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-12-2015 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 4Q-2014 Light | Biotechnology | Download | biotechnology |
03-10-2015 | Concordia International Corp. | TSX: CXR | Big Accretive Acquisition Bumps Target Price Again | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
03-04-2015 | Tribute Pharmaceuticals Canada Inc. | TSX-V: TRX | 4Q-2014 in line. Early signs investment is paying off | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
02-09-2015 | Aurinia Pharmaceuticals Inc. | NASDAQ:AUPH | Initiation of AURION Study | Biotechnology | Download | biotechnology |
01-27-2015 | Tribute Pharmaceuticals Canada Inc. | TSX-V: TRX | Key Growth Drivers Making an Impact. Overall Q4-2014 Revenue Guidance Base Slightly Below Estimates | Specialty Pharmaceutical | Download | specialty-pharmaceutical |
12-18-2014 | Healthcare Sector Overview | | Research Initiation – Healthcare Sector Overview | Biotechnology, Specialty Pharmaceutical | Download | biotechnology specialty-pharmaceutical |
03-13-2014 | DISCONTINUED RESEARCH | | Discontinuing research coverage | Biotechnology | Download | biotechnology |
03-03-2014 | PALADIN LABS INC. | TSX:PLB | Discontinuing research coverage | Biotechnology | Download | biotechnology |
02-28-2014 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | TTH reclaims ELND005 rights and benefits associated with Irishdomiciled subsidiary. Increasing price target to $7.00 | Biotechnology | Download | biotechnology |
02-27-2014 | Theratechnologies Inc. | TSX:TH | F2013 results reported. No answers yet on Egrifta supply issues | Biotechnology | Download | biotechnology |
02-21-2014 | Nuvo Research Inc. | TSX:NRI | 2013 results leave us concerned about strength of balance sheet | Biotechnology | Download | biotechnology |
02-20-2014 | Trimel Pharmaceuticals Inc. | TSX:TRL | $10.5 million private placement adds a cash cushion while we wait for an FDA response | Biotechnology | Download | biotechnology |
02-20-2014 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | CRME capitalizes on attractive share price and raises C$15 million | Biotechnology | Download | biotechnology |
02-18-2014 | Theratechnologies Inc. | TSX:TH | Downgrading to Sell on continued manufacturing issues and stockouts; price target to $0.30 | Biotechnology | Download | biotechnology |
02-18-2014 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | “At the market” offering to bolster the balance sheet | Biotechnology | Download | biotechnology |
02-13-2014 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q2 F2014 results as expected. New compound expected to be inlicensed soon | Biotechnology | Download | biotechnology |
01-27-2014 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Re-treatment data from QLT091001 too preliminary for any conclusions | Biotechnology | Download | biotechnology |
01-23-2014 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Raising price target to $7.50 for upside re potential sale of business | Biotechnology | Download | biotechnology |
01-17-2014 | Nuvo Research Inc. | TSX:NRI | Pennsaid 2% approved; now we wait for sales numbers | Biotechnology | Download | biotechnology |
01-17-2014 | Trimel Pharmaceuticals Inc. | TSX:TRL | CompleoTRT PDUFA date pushed back to May 28, 2014 | Biotechnology | Download | biotechnology |
01-10-2014 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 2013 revenues expected to be $7.68 million. Price target reverts back to $0.70 | Biotechnology | Download | biotechnology |
01-10-2014 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 2013 revenues expected to be $7.86 million. Upping price target to $0.80 | Biotechnology | Download | biotechnology |
01-09-2014 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | AEZS raises $13.2 million less than 2 months after last raise | Biotechnology | Download | biotechnology |
01-06-2014 | Canadian Healthcare | | Navigating the Canadian Biotech Space | Biotechnology | Download | biotechnology |
12-20-2013 | Trimel Pharmaceuticals Inc. | TSX:TRL | TRL elects to pursue only three times daily dosing for CompleoTRT. Lowering price target to $0.75 and rating to Hold | Biotechnology | Download | biotechnology |
12-13-2013 | Theratechnologies Inc. | TSX:TH | TH regains U.S Egrifta rights at a cost of US$20 million + royalties. Rating to Hold; price target to $0.50 | Biotechnology | Download | biotechnology |
12-11-2013 | PALADIN LABS INC. | TSX:PLB | More details about PLB acquisition revealed in Proxy Statement | Biotechnology | Download | biotechnology |
11-26-2013 | PALADIN LABS INC. | TSX:PLB | Who is the most likely purchaser of a priority review voucher? | Biotechnology | Download | biotechnology |
11-21-2013 | QLT INC. | NASDAQ: QLTI; TSX:QLT | QLTI evaluating strategic alternatives. Pivotal retinoid program could start in H1 2014 | Biotechnology | Download | biotechnology |
11-21-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Phase III head & neck data doesn’t shed much light, in our view | Biotechnology | Download | biotechnology |
11-20-2013 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | AEZS once again taps the market for more cash | Biotechnology | Download | biotechnology |
11-19-2013 | Oncolytics Biotech Inc. | NASDAQ: OGXI | SYNERGY trial continues after interim analysis | Biotechnology | Download | biotechnology |
11-19-2013 | Cardiome Pharma Corp. | NASDAQ:CRME, TSX:COM | CRME transforms itself with acquisition of Correvio. Price target upped to $3.25 | Biotechnology | Download | biotechnology |
11-14-2013 | PALADIN LABS INC. | TSX:PLB | Q3 2013 results not as important now that PLB is expected to be acquired | Biotechnology | Download | biotechnology |
11-13-2013 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q1 F2014 results in line. Waiting for news from partners’ clinical development activities | Biotechnology | Download | biotechnology |
11-12-2013 | PALADIN LABS INC. | TSX:PLB | FDA review of Impavido extended by three months | Biotechnology | Download | biotechnology |
11-08-2013 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | SYNERGY phase III results still expected mid-2014 | Biotechnology | Download | biotechnology |
11-07-2013 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Q3 2013 results. Waiting for strategy for QLT091001 | Biotechnology | Download | biotechnology |
11-07-2013 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | CRME working hard to realize Brinavess potential | Biotechnology | Download | biotechnology |
11-07-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q3 2013 results show no surprises | Biotechnology | Download | biotechnology |
11-06-2013 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q3 2013 results favourably impacted by acceleration of Cetrotide deferred revenue | Biotechnology | Download | biotechnology |
11-05-2013 | PALADIN LABS INC. | TSX:PLB | PALADIN LABS INC. (TSX:PLB; $62.98) | Biotechnology | Download | biotechnology |
11-04-2013 | Trimel Pharmaceuticals Inc. | TSX:TRL | Q3 2013 results. Scenario analysis for CompleoTRT. Lowering target to $1.50 | Biotechnology | Download | biotechnology |
11-04-2013 | Theratechnologies Inc. | TSX:TH | Health Canada to resume tesamorelin review | Biotechnology | Download | biotechnology |
10-31-2013 | Nuvo Research Inc. | TSX:NRI | Q3 2013 results affected by one-time items. Decision on Pennsaid 2% next major event | Biotechnology | Download | biotechnology |
10-29-2013 | CRH Medical Corp. | TSX:CRH | Q3 2013 financials in line | Biotechnology | Download | biotechnology |
10-28-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | ONC highlights NSCLC data | Biotechnology | Download | biotechnology |
10-25-2013 | Trimel Pharmaceuticals Inc. | TSX:TRL | TRL faces its own FDA stumbling block. Partnering delays likely. Price target lowered to $2.00 | Biotechnology | Download | biotechnology |
10-24-2013 | Trimel Pharmaceuticals Inc. | TSX:TRL | Development of a CompleoTRT competitor hits a speed bump | Biotechnology | Download | biotechnology |
10-23-2013 | Trimel Pharmaceuticals Inc. | TSX:TRL | Development of a CompleoTRT competitor hits a speed bump | Biotechnology | Download | biotechnology |
10-18-2013 | PALADIN LABS INC. | TSX:PLB | FDA advisory committee votes in favour of Impavido | Biotechnology | Download | biotechnology |
10-16-2013 | PALADIN LABS INC. | TSX:PLB | FDA publishes Impavido advisory committee briefing documents | Biotechnology | Download | biotechnology |
10-10-2013 | Theratechnologies Inc. | TSX:TH | Q3 F2013 expenses high as TH tackles manufacturing issues | Biotechnology | Download | biotechnology |
10-01-2013 | CML Healthcare Inc. | TSX:CLC | Discontinuing research coverage | Biotechnology | Download | biotechnology |
10-01-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | More Reolysin data, but not what we’re waiting for | Biotechnology | Download | biotechnology |
09-23-2013 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | CRME stock surging; awaiting H2 results to see vernakalant sales | Biotechnology | Download | biotechnology |
09-19-2013 | Theratechnologies Inc. | TSX:TH | Manufacturing issues continue to impact Egrifta® | Biotechnology | Download | biotechnology |
09-18-2013 | Medicago Inc. | TSX:MDG | Discontinuing research coverage | Biotechnology | Download | biotechnology |
09-12-2013 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | F2013 results reported. Product development continuing as expected | Biotechnology | Download | biotechnology |
09-09-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Final lung cancer tumour response data consistent with earlier reports | Biotechnology | Download | biotechnology |
08-26-2013 | Trimel Pharmaceuticals Inc. | TSX:TRL | Initiating coverage with a Buy rating and C$2.25 target | Biotechnology | Download | biotechnology |
08-21-2013 | Nuvo Research Inc. | TSX:NRI | NRI fights back | Biotechnology | Download | biotechnology |
08-14-2013 | PALADIN LABS INC. | TSX:PLB | Upping price target to $61.00 due to strong business performance and rising sector multiples | Biotechnology | Download | biotechnology |
08-09-2013 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | R&D spend rising in Q2 to support development. Custirsen phase III data pushed back to mid-2014 | Biotechnology | Download | biotechnology |
08-09-2013 | CML Healthcare Inc. | TSX:CLC | On track for acquisition by Lifelabs | Biotechnology | Download | biotechnology |
08-09-2013 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q2 2013 results impacted by acceleration of Cetrotide deferred revenue. Moving towards being a commercial company | Biotechnology | Download | biotechnology |
08-06-2013 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | TTH raises US$11 million in private placement | Biotechnology | Download | biotechnology |
08-02-2013 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Lowering price target to $5.50 and rating to Hold post shareholder payout | Biotechnology | Download | biotechnology |
08-02-2013 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Q2 2013 results show rising costs to support Brinavess sales | Biotechnology | Download | biotechnology |
08-01-2013 | Nuvo Research Inc. | TSX:NRI | Q2 2013 results show weak Pennsaid sales. Strategy shifts to WF-10 | Biotechnology | Download | biotechnology |
08-01-2013 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Q2 2013 results. Waiting for QLT091001 development plan | Biotechnology | Download | biotechnology |
08-01-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q2 2013 results. Scenario analysis for Reolysin | Biotechnology | Download | biotechnology |
07-25-2013 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | AEZS raises $7.8 million. Lowering price target to $0.75 | Biotechnology | Download | biotechnology |
07-24-2013 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Déjà vu – TTH and LLY partner up again | Biotechnology | Download | biotechnology |
07-23-2013 | CRH Medical Corp. | TSX:CRH | Q2 2013 financials in line with estimates | Biotechnology | Download | biotechnology |
07-22-2013 | Nuvo Research Inc. | TSX:NRI | Update on NRI after licensing U.S. Synera rights | Biotechnology | Download | biotechnology |
07-22-2013 | Medicago Inc. | TSX:MDG | Increasing price target to $1.16 due to Mitsubishi Tanabe Pharma proposed acquisition | Biotechnology | Download | biotechnology |
07-10-2013 | Theratechnologies Inc. | TSX:TH | U.S. Egrifta sales in Q2 F2013 improved over previous year but flat sequentially | Biotechnology | Download | biotechnology |
07-03-2013 | Canadian Healthcare | | Navigating the Canadian Biotech Space | Biotechnology | Download | biotechnology |
06-25-2013 | CML Healthcare Inc. | TSX:CLC | CLC to be acquired for $10.75 per share | Biotechnology | Download | biotechnology |
06-17-2013 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Lilly opts to develop TT-401. Price target upped to $3.50 | Biotechnology | Download | biotechnology |
06-06-2013 | Medicago Inc. | TSX:MDG | MDG announces positive H7N9 preclinical data | Biotechnology | Download | biotechnology |
06-06-2013 | PALADIN LABS INC. | TSX:PLB | “Bank of Paladin” makes two more investments | Biotechnology | Download | biotechnology |
06-05-2013 | Medicago Inc. | TSX:MDG | Rating lowered to Hold on share price appreciation; we await outcome of pharma negotiations | Biotechnology | Download | biotechnology |
05-16-2013 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Update post Q1 2013 results | Biotechnology | Download | biotechnology |
05-13-2013 | Medicago Inc. | TSX:MDG | Q1 2013 results slightly ahead of our estimates. Future depends on signing lucrative contracts | Biotechnology | Download | biotechnology |
05-09-2013 | Nuvo Research Inc. | TSX:NRI | 65:1 share consolidation | Biotechnology | Download | biotechnology |
05-09-2013 | PALADIN LABS INC. | TSX:PLB | Q1 2013 results appear solid. Upping target to $52 but lowering rating to Hold due to recent share price gains | Biotechnology | Download | biotechnology |
05-09-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q1 2013 results. Reolysin survival data now predicted for H2 | Biotechnology | Download | biotechnology |
05-08-2013 | CML Healthcare Inc. | TSX:CLC | Q1 2013 financials lower than consensus; CLC laying the groundwork for the future | Biotechnology | Download | biotechnology |
05-08-2013 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q1 2013 results impacted by one-time non-cash items | Biotechnology | Download | biotechnology |
05-08-2013 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q3 F2013 financial results as expected. Waiting for a decision on TT401 | Biotechnology | Download | biotechnology |
05-03-2013 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Raising target to $25.00 on back of Q1 cost efficiencies | Biotechnology | Download | biotechnology |
05-03-2013 | PALADIN LABS INC. | TSX:PLB | Q1 2013 Preview | Biotechnology | Download | biotechnology |
05-02-2013 | Nuvo Research Inc. | TSX:NRI | A disappointing start to the year. Expect a challenging year ahead | Biotechnology | Download | biotechnology |
05-02-2013 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Q1 2013 financials show cost savings from restructuring | Biotechnology | Download | biotechnology |
05-01-2013 | CML Healthcare Inc. | TSX:CLC | Western expansion with small acquisition | Biotechnology | Download | biotechnology |
04-30-2013 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Early TT-401 data look promising | Biotechnology | Download | biotechnology |
04-25-2013 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Brinavess rights transitioned back to Cardiome | Biotechnology | Download | biotechnology |
04-24-2013 | CRH Medical Corp. | TSX:CRH | Q1 2013 financials mostly in line. Lowering rating to Hold due to implied return to target | Biotechnology | Download | biotechnology |
04-18-2013 | Medicago Inc. | TSX:MDG | IDRI phase I H5N1 vaccine results positive; new adjuvant not better | Biotechnology | Download | biotechnology |
04-15-2013 | QLT INC. | NASDAQ: QLTI; TSX:QLT | QLTI proposes tax-efficient $200 million cash distribution to shareholders | Biotechnology | Download | biotechnology |
04-15-2013 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 5:1 share consolidation to gain NASDAQ compliance | Biotechnology | Download | biotechnology |
04-11-2013 | Theratechnologies Inc. | TSX:TH | Q1 F2013 results show profit due to lease renegotiation. Manufacturing QA issues arise. Production suspended | Biotechnology | Download | biotechnology |
04-10-2013 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Agreement with Ergomed to share costs of AEZS-108 phase III trial | Biotechnology | Download | biotechnology |
04-09-2013 | Medicago Inc. | TSX:MDG | What we’re looking for in April 17th IDRI pandemic flu results | Biotechnology | Download | biotechnology |
04-08-2013 | Theratechnologies Inc. | TSX:TH | Ferrer hands back Egrifta® | Biotechnology | Download | biotechnology |
04-08-2013 | CML Healthcare Inc. | TSX:CLC | Automation of microbiology analyses to increase efficiency | Biotechnology | Download | biotechnology |
04-03-2013 | CML Healthcare Inc. | TSX:CLC | CML Healthcare – Diagnosis: On the road to recovery | Biotechnology | Download | biotechnology |
04-01-2013 | Medicago Inc. | TSX:MDG | 2012 results show high expense level | Biotechnology | Download | biotechnology |
03-28-2013 | Nuvo Research Inc. | TSX:NRI | Q4 2012 Pennsaid sales disappointing. Lowering target to $0.05 given our 2013 outlook | Biotechnology | Download | biotechnology |
03-22-2013 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | 2013 could be a challenging year with few value-inflection points. Lowering price target to $1.50 | Biotechnology | Download | biotechnology |
03-21-2013 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 2012 financial results no surprises | Biotechnology | Download | biotechnology |
03-20-2013 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | 2012 results. Can CRME be more successful than big pharma with direct sales of Brinavess? | Biotechnology | Download | biotechnology |
03-20-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Competitor oncolytic virus gets positive results in melanoma | Biotechnology | Download | biotechnology |
03-14-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | 2012 results: Don’t expect controlled Reolysin data until H2 2013 | Biotechnology | Download | biotechnology |
03-11-2013 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Perifosine fails again in phase III trial | Biotechnology | Download | biotechnology |
03-08-2013 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | 2012 results show OGX-427 R&D spend high. Key year ahead | Biotechnology | Download | biotechnology |
03-05-2013 | Nuvo Research Inc. | TSX:NRI | Pennsaid 2% gets FDA Complete Response Letter | Biotechnology | Download | biotechnology |
03-04-2013 | Theratechnologies Inc. | TSX:TH | Egrifta® rejected by Health Canada | Biotechnology | Download | biotechnology |
03-04-2013 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Settlement of debt and launch of salesforce | Biotechnology | Download | biotechnology |
02-28-2013 | PALADIN LABS INC. | TSX:PLB | 2012 results impacted by integration costs. PLB well positioned for 2013 and beyond | Biotechnology | Download | biotechnology |
02-27-2013 | Theratechnologies Inc. | TSX:TH | F2012 results impacted by restructuring charges | Biotechnology | Download | biotechnology |
02-25-2013 | QLT INC. | NASDAQ: QLTI; TSX:QLT | 2012 results ahead of estimates due to low R&D | Biotechnology | Download | biotechnology |
02-21-2013 | PALADIN LABS INC. | TSX:PLB | Erratum: Q4 and 2012 Preview | Biotechnology | Download | biotechnology |
02-20-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | ONC raises US$32 million in equity offering to bolster balance sheet | Biotechnology | Download | biotechnology |
02-20-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Raising capital ahead of head & neck cancer data | Biotechnology | Download | biotechnology |
02-14-2013 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Possible outcomes from perifosine interim analysis | Biotechnology | Download | biotechnology |
02-11-2013 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Discontinuing research coverage | Biotechnology | Download | biotechnology |
02-08-2013 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | TT401/402 data expected in Q2; financial results as expected | Biotechnology | Download | biotechnology |
02-08-2013 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Additional interim phase II lung data supports previous results | Biotechnology | Download | biotechnology |
01-29-2013 | Nuvo Research Inc. | TSX:NRI | Pennsaid generic risk mitigated in the short-term | Biotechnology | Download | biotechnology |
01-28-2013 | Medicago Inc. | TSX:MDG | MDG enters into plant production collaboration | Biotechnology | Download | biotechnology |
01-28-2013 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Initation of retinoid phase III trials delayed as QLTI seeks FDA input | Biotechnology | Download | biotechnology |
01-17-2013 | Medicago Inc. | TSX:MDG | MDG raises $15 million in non-dilutive loan | Biotechnology | Download | biotechnology |
01-17-2013 | PALADIN LABS INC. | TSX:PLB | Price target increased to $51.00; expecting another year of growth | Biotechnology | Download | biotechnology |
01-15-2013 | Diagnocure Inc. | TSX:CUR | Discontinuing research coverage | Biotechnology | Download | biotechnology |
01-15-2013 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 2012 revenues expected at $6.85 million. Lowering price target to $0.50 | Biotechnology | Download | biotechnology |
01-03-2013 | Canadian Healthcare | | Navigating the Canadian Biotech Space | Biotechnology | Download | biotechnology |
12-24-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Option agreement reached on sale of punctal plug. Lowering target to $9.00 | Biotechnology | Download | biotechnology |
12-18-2012 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Lowering rating to Hold after favourable reaction to interim Reolysin data | Biotechnology | Download | biotechnology |
12-17-2012 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Updated rating and price target post Gilead acquisition | Biotechnology | Download | biotechnology |
12-10-2012 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Updated CYT387 data presented at ASH 2012 | Biotechnology | Download | biotechnology |
12-06-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Additional restructuring and job losses at QLTI | Biotechnology | Download | biotechnology |
12-04-2012 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Losing nimo: YM divests the asset. Stage set for CYT387 development | Biotechnology | Download | biotechnology |
11-20-2012 | PALADIN LABS INC. | TSX:PLB | Start of Latin American expansion with Ativa Pharma investment. | Biotechnology | Download | biotechnology |
11-15-2012 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Future remains uncertain. Lowering rating to Sell, price target to $0.10 | Biotechnology | Download | biotechnology |
11-14-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q3 2012 results. Multiple myeloma interim data the key next step | Biotechnology | Download | biotechnology |
11-13-2012 | PALADIN LABS INC. | TSX:PLB | One-time Litha-related charges favourably impact Q3 results. Target lowered to $46.00 | Biotechnology | Download | biotechnology |
11-12-2012 | Medicago Inc. | TSX:MDG | Q3 results reveal temporary delays in development. | Biotechnology | Download | biotechnology |
11-12-2012 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | No surprises in Q1 F2013 results | Biotechnology | Download | biotechnology |
11-08-2012 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Large increase in R&D spend impacts Q3 2012 results | Biotechnology | Download | biotechnology |
11-08-2012 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q1 F2013 results in line | Biotechnology | Download | biotechnology |
11-08-2012 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q3 2012 EPS ($0.12); we wait for Reolysin results | Biotechnology | Download | biotechnology |
11-07-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Restructuring charges impact Q3 2012. Focus on retinoid program | Biotechnology | Download | biotechnology |
11-05-2012 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | ASH 2012 abstract provides little additional data. Wait for December presentation | Biotechnology | Download | biotechnology |
11-01-2012 | Nuvo Research Inc. | TSX:NRI | Q3 2012 results disappoint. Potential for a generic Pennsaid any day. Lowering price target to $0.07 | Biotechnology | Download | biotechnology |
10-30-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | Stormy times continue…updated strategic plan cuts more staff | Biotechnology | Download | biotechnology |
10-25-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Punctal plug data show improved retention over previous results | Biotechnology | Download | biotechnology |
10-22-2012 | Nuvo Research Inc. | TSX:NRI | Pliaglis® approved by FDA | Biotechnology | Download | biotechnology |
10-18-2012 | Medicago Inc. | TSX:MDG | Competitor reports favourable phase I H5N1 flu vaccine results | Biotechnology | Download | biotechnology |
10-12-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | CEO departs; new business plan in development | Biotechnology | Download | biotechnology |
10-12-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | $16.5 million raise provides more capital but at significant dilution | Biotechnology | Download | biotechnology |
10-10-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | Update on Egrifta® regulatory issues; no major changes | Biotechnology | Download | biotechnology |
10-09-2012 | CRH Medical Corp. | TSX:CRH | Q3 2012 results in line. Waiting to see impact of top-line focus | Biotechnology | Download | biotechnology |
10-04-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | 6:1 share consolidation to regain compliance with NASDAQ | Biotechnology | Download | biotechnology |
10-02-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Share repurchase plan announced | Biotechnology | Download | biotechnology |
09-26-2012 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | MRK hands back vernakalant rights | Biotechnology | Download | biotechnology |
09-25-2012 | Medicago Inc. | TSX:MDG | Chinese rights to flu vaccine licensed to Philip Morris | Biotechnology | Download | biotechnology |
09-24-2012 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Awaiting either a partner or the start of phase III trials | Biotechnology | Download | biotechnology |
09-24-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Sale of Visudyne® to Valeant; strategic plan on track | Biotechnology | Download | biotechnology |
09-14-2012 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | F2012 costs under control. Increasing price target to $2.50 | Biotechnology | Download | biotechnology |
09-12-2012 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Like waiting for Godot…still no Reolysin data. Lowering target to $4.00 due to expected delays in time to market | Biotechnology | Download | biotechnology |
09-07-2012 | Diagnocure Inc. | TSX:CUR | Previstage sales stopped. Progensa future uncertain. Lowering rating to Sell, price target to $0.50 | Biotechnology | Download | biotechnology |
08-30-2012 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | ELND005 phase II bipolar disease trial starts | Biotechnology | Download | biotechnology |
08-30-2012 | PALADIN LABS INC. | TSX:PLB | Upgrading to Buy from Hold. South African pharma market expected to grow | Biotechnology | Download | biotechnology |
08-23-2012 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Future strategy of CRME still up in the air | Biotechnology | Download | biotechnology |
08-20-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Summary of Q2 2012 results | Biotechnology | Download | biotechnology |
08-09-2012 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Lowering price target to $0.30 as Brinavess sales appear low. Awaiting strategic update | Biotechnology | Download | biotechnology |
08-08-2012 | Medicago Inc. | TSX:MDG | Q2 2012 results as expected | Biotechnology | Download | biotechnology |
08-08-2012 | CRH Medical Corp. | TSX:CRH | Q2 2012 results sequentially flat. Lowering price target to $1.00 | Biotechnology | Download | biotechnology |
08-02-2012 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Q2 2012 results better than expected | Biotechnology | Download | biotechnology |
08-02-2012 | Nuvo Research Inc. | TSX:NRI | Q2 2012 profit results from US$5.0 million Pliaglis milestone | Biotechnology | Download | biotechnology |
08-02-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Q2 2012 results; Visudyne losing market share. Expenses high until restructuring complete | Biotechnology | Download | biotechnology |
08-02-2012 | PALADIN LABS INC. | TSX:PLB | Q2 2012 results show slower growth; H2 2012 expected to be strong | Biotechnology | Download | biotechnology |
08-02-2012 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q2 2012 EPS ($0.13). Patiently waiting for Reolysin data | Biotechnology | Download | biotechnology |
07-26-2012 | PALADIN LABS INC. | TSX:PLB | Q2 2012 Preview | Biotechnology | Download | biotechnology |
07-24-2012 | Medicago Inc. | TSX:MDG | Successful production of 10 million pandemic flu vaccine doses | Biotechnology | Download | biotechnology |
07-24-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | AEZS requests Fast Track designation for Solorel™ | Biotechnology | Download | biotechnology |
07-23-2012 | Nuvo Research Inc. | TSX:NRI | Pennsaid® gets new use patent; generics apply for approval | Biotechnology | Download | biotechnology |
07-20-2012 | Medicago Inc. | TSX:MDG | Revising model as timing of revenues appears at risk. Lowering price target to $0.75 | Biotechnology | Download | biotechnology |
07-19-2012 | PALADIN LABS INC. | TSX:PLB | Update from management affirms our positive outlook. Rating lowered to Hold due to share price appreciation | Biotechnology | Download | biotechnology |
07-18-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | European regulators provide reasons for Egrifta application concerns | Biotechnology | Download | biotechnology |
07-12-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | Q2 F2012 results slightly ahead of consensus | Biotechnology | Download | biotechnology |
07-11-2012 | Canadian Healthcare | | Navigating the Canadian Biotech Space | Biotechnology | Download | biotechnology |
07-09-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Shake-up at QLTI. Sole focus is QLT091001 | Biotechnology | Download | biotechnology |
07-09-2012 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | More workforce reductions; little upside remains | Biotechnology | Download | biotechnology |
07-03-2012 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | CEO departs; expect strategic update by mid-August | Biotechnology | Download | biotechnology |
06-27-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | Tesamorelin in obese patients results in VAT reductions; no impact on weight | Biotechnology | Download | biotechnology |
06-26-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Final Solorel™ phase III results | Biotechnology | Download | biotechnology |
06-25-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | Tesamorelin approvals in Canada and EU unlikely. Lowering rating to Sell from Hold, price target to $0.75 | Biotechnology | Download | biotechnology |
06-20-2012 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Reolysin safety OK; still awaiting PFS data from first stage of trial | Biotechnology | Download | biotechnology |
06-19-2012 | Medicago Inc. | TSX:MDG | U.S. government provides US$400 million in funding for pandemic preparedness | Biotechnology | Download | biotechnology |
06-11-2012 | Diagnocure Inc. | TSX:CUR | Recap of Q2 F2012 results | Biotechnology | Download | biotechnology |
06-05-2012 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | ASCO highlights – OGX-427 continues to show promise | Biotechnology | Download | biotechnology |
06-05-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | New Board of Directors elected | Biotechnology | Download | biotechnology |
05-31-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | QLTI proposes one-time dividend or Dutch auction to return capital | Biotechnology | Download | biotechnology |
05-29-2012 | PALADIN LABS INC. | TSX:PLB | Jonathan Goodman returns to PLB as Chairman | Biotechnology | Download | biotechnology |
05-28-2012 | Nuvo Research Inc. | TSX:NRI | Synera® licensed to Paladin Labs for Canada; NRI receives up to $8 million loan | Biotechnology | Download | biotechnology |
05-28-2012 | PALADIN LABS INC. | TSX:PLB | PLB licenses Synera® from Nuvo Research; provides up to $8 million loan | Biotechnology | Download | biotechnology |
05-25-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | QLTI defers AGM, highlights product progress, proposes modified Dutch auction | Biotechnology | Download | biotechnology |
05-23-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | QLT shareholder aims to modify Board, but no future plans identified | Biotechnology | Download | biotechnology |
05-22-2012 | Diagnocure Inc. | TSX:CUR | PSA testing no longer recommended | Biotechnology | Download | biotechnology |
05-15-2012 | Medicago Inc. | TSX:MDG | Q1 2012 results. High R&D as DARPA contract coming to an end | Biotechnology | Download | biotechnology |
05-14-2012 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Q1 2012 losses lower than expected. Strategic update expected within 2 months | Biotechnology | Download | biotechnology |
05-11-2012 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Q3 F2012 results better than expected | Biotechnology | Download | biotechnology |
05-10-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | ARVO update expands on efficacy and safety of QLT091001 | Biotechnology | Download | biotechnology |
05-10-2012 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q1 2012 EPS ($0.11). Reolysin interim data may be imminent | Biotechnology | Download | biotechnology |
05-09-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q1 2012 results. Product development appears slow | Biotechnology | Download | biotechnology |
05-09-2012 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q3 F2012 results in line | Biotechnology | Download | biotechnology |
05-07-2012 | Nuvo Research Inc. | TSX:NRI | Positive Pliaglis recommendation from German regulators | Biotechnology | Download | biotechnology |
05-07-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | AEZS regains perifosine rights; continues with multiple myeloma study | Biotechnology | Download | biotechnology |
05-04-2012 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | No major surprises in Q1 results. Expect R&D to ramp up in H2; price target lowered to $18.00 | Biotechnology | Download | biotechnology |
05-03-2012 | Nuvo Research Inc. | TSX:NRI | Q1 2012 results show Pennsaid growth but trends unlikely to continue. Lowering price target to $0.10 | Biotechnology | Download | biotechnology |
05-03-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Q1 2012 EPS ($0.21); R&D spend high as progressing to phase III | Biotechnology | Download | biotechnology |
05-03-2012 | PALADIN LABS INC. | TSX:PLB | Q1 2012 beats ‘the Street’. Another record quarter | Biotechnology | Download | biotechnology |
04-26-2012 | CRH Medical Corp. | TSXV:CRM | Q1 2012 results continue to show growth. Upgrading to Buy, price target to $1.25 | Biotechnology | Download | biotechnology |
04-26-2012 | PALADIN LABS INC. | TSX:PLB | Q1 2012 – Expecting an OK quarter but H2 2012 likely to improve | Biotechnology | Download | biotechnology |
04-24-2012 | CRH Medical Corp. | TSXV:CRM | Revenues ramping up. Profit improving | Biotechnology | Download | biotechnology |
04-18-2012 | Nuvo Research Inc. | TSX:NRI | A bump in the road for Pliaglis® | Biotechnology | Download | biotechnology |
04-13-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | Q1 F2012 results impacted by restructuring costs | Biotechnology | Download | biotechnology |
04-12-2012 | QLT INC. | NASDAQ: QLTI; TSX:QLT | Eyeing the future: Initiating coverage with Buy rating, $10.00 target | Biotechnology | Download | biotechnology |
04-11-2012 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Upgrading to Hold due to price depreciation | Biotechnology | Download | biotechnology |
04-09-2012 | Nuvo Research Inc. | TSX:NRI | Pennsaid® sales surge on Voltaren® Gel shortages. Price target increased to $0.14 | Biotechnology | Download | biotechnology |
04-09-2012 | Diagnocure Inc. | TSX:CUR | Q1 F2012 results recap | Biotechnology | Download | biotechnology |
04-02-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Perifosine fails to show survival improvement in colorectal cancer. Lowering rating to Sell, price target to $0.50 | Biotechnology | Download | biotechnology |
04-02-2012 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | 80th patient recruited into head & neck cancer trial | Biotechnology | Download | biotechnology |
03-30-2012 | Medicago Inc. | TSX:MDG | 2011 financial results essentially in line with our forecasts | Biotechnology | Download | biotechnology |
03-28-2012 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | F2011 results and view post oral vernakalant discontinuation. Price target lowered to $0.60 | Biotechnology | Download | biotechnology |
03-28-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | 2011 results benefit from higher revenues. Phase III perifosine results could come in May 2012 | Biotechnology | Download | biotechnology |
03-26-2012 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Updating estimates post $57.5 million equity offering. Price target lowered to $19.00 | Biotechnology | Download | biotechnology |
03-15-2012 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | 2011 EPS ($0.41). Reolysin data now appears delayed to Q2 | Biotechnology | Download | biotechnology |
03-12-2012 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Update on YM post equity offering of US$80.5 million | Biotechnology | Download | biotechnology |
03-09-2012 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | As the prostate cancer market turns, custirsen development plan evolves. Price target lowered to $24.00 | Biotechnology | Download | biotechnology |
03-06-2012 | Medicago Inc. | TSX:MDG | Mitsubishi collaboration to bring in revenue stream. Price target to $1.25 | Biotechnology | Download | biotechnology |
02-27-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | Quebec Court authorizes class action suit | Biotechnology | Download | biotechnology |
02-21-2012 | Nuvo Research Inc. | TSX:NRI | Pliaglis on track for EU and U.S. launches in H2 2012 | Biotechnology | Download | biotechnology |
02-21-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | TH inks Canadian distribution deal for tesamorelin | Biotechnology | Download | biotechnology |
02-21-2012 | PALADIN LABS INC. | TSX:PLB | PLB builds its South African presence. Price target increased to $50.00 | Biotechnology | Download | biotechnology |
02-17-2012 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | ERRATUM – Reolysin interim data coming soon. Price target lowered to $7.50 | Biotechnology | Download | biotechnology |
02-16-2012 | PALADIN LABS INC. | TSX:PLB | Record 2011 revenues but future growth forecasts are flat. Price target to $48.00 | Biotechnology | Download | biotechnology |
02-15-2012 | Diagnocure Inc. | TSX:CUR | Progensa™ PCA3 assay receives FDA approval | Biotechnology | Download | biotechnology |
02-09-2012 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Q2 F2012 results as expected. Competitive JAK landscape examined | Biotechnology | Download | biotechnology |
02-09-2012 | PALADIN LABS INC. | TSX:PLB | Q4 2011 preview: Expecting a strong finish to 2011. Upping price target to $49.00 | Biotechnology | Download | biotechnology |
02-08-2012 | Theratechnologies Inc. | TSX:TH; Q:THER | F2011 results show low revenue growth; expenses under control | Biotechnology | Download | biotechnology |
02-02-2012 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | OGX-427 prostate cancer data highly encouraging | Biotechnology | Download | biotechnology |
02-02-2012 | Nuvo Research Inc. | TSX:NRI | Synera® re-launched in the U.S | Biotechnology | Download | biotechnology |
01-30-2012 | Diagnocure Inc. | TSX:CUR | Summarizing Q4 F2011 results. Lowering price target to $1.00 | Biotechnology | Download | biotechnology |
01-24-2012 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | AEZS announces another “At the Market” offering of up to $16 million | Biotechnology | Download | biotechnology |
01-19-2012 | Medicago Inc. | TSX:MDG | MDG announces development of a rabies vaccine | Biotechnology | Download | biotechnology |
01-16-2012 | Medicago Inc. | TSX:MDG | MDG signs research agreement with Cellectis | Biotechnology | Download | biotechnology |
01-04-2012 | Canadian Healthcare | | Navigating the Canadian Biotech Space | Biotechnology | Download | biotechnology |
12-15-2011 | Nuvo Research Inc. | TSX:NRI | U.S. partner plans to spin off pharma business | Biotechnology | Download | biotechnology |
12-13-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | On the 12th day of Christmas…12 weeks of transfusion independence | Biotechnology | Download | biotechnology |
12-07-2011 | Theratechnologies Inc. | TSX:THTSX:TH; Q:THER | Discontinuation of COPD program and downsizing to save costs. Lowering price target to $2.50 | Biotechnology | Download | biotechnology |
12-05-2011 | Nuvo Research Inc. | TSX:NRI | Acquisition of remaining 40% of German subsidiary | Biotechnology | Download | biotechnology |
12-02-2011 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q1 F2012 results. TTH manages its cash flow. Increasing target to $2.00 | Biotechnology | Download | biotechnology |
11-29-2011 | PALADIN LABS INC. | TSX:PLB | PLB in-licenses Travelan® | Biotechnology | Download | biotechnology |
11-23-2011 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Perifosine licensed to Hikma for the Middle East and North Africa | Biotechnology | Download | biotechnology |
11-21-2011 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | US$5 million private placement to bolster the balance sheet. Lowering target to $1.50 | Biotechnology | Download | biotechnology |
11-17-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Competitor JAK1/2 inhibitor approved by the FDA | Biotechnology | Download | biotechnology |
11-15-2011 | Nuvo Research Inc. | TSX:NRI | Pennsaid® samples cease to be distributed | Biotechnology | Download | biotechnology |
11-15-2011 | Medicago Inc. | TSX:MDG | Q3 2011 EPS ($0.03). North Carolina facility ramping up for business | Biotechnology | Download | biotechnology |
11-14-2011 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Reolysin shows signs of activity | Biotechnology | Download | biotechnology |
11-12-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Q1 F2012 operational results in line. Lowering target to $4.00 due to lower nimotuzumab forecasts | Biotechnology | Download | biotechnology |
11-10-2011 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Merck R&D briefing confirms vernakalant development plans | Biotechnology | Download | biotechnology |
11-10-2011 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q3 2011 operational results in line. Waiting for perifosine data | Biotechnology | Download | biotechnology |
11-10-2011 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q3 2011 EPS ($0.09). Progressing towards first stage phase III results | Biotechnology | Download | biotechnology |
11-08-2011 | Diagnocure Inc. | TSX:CUR | Partner confirms no FDA panel meeting necessary. Could approval be forthcoming? | Biotechnology | Download | biotechnology |
11-07-2011 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Q3 EPS ($0.12). Looking for an update at Merck’s R&D briefing | Biotechnology | Download | biotechnology |
11-07-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Latest CYT387 data supports safety profile | Biotechnology | Download | biotechnology |
11-04-2011 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Q3 2011 operating expenses low but R&D expected to ramp up | Biotechnology | Download | biotechnology |
11-04-2011 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Vernakalant oral development slows to a crawl. Lowering rating to Sell | Biotechnology | Download | biotechnology |
11-04-2011 | PALADIN LABS INC. | TSX:PLB | PLB continues its winning ways with a strong Q3 | Biotechnology | Download | biotechnology |
11-03-2011 | Nuvo Research Inc. | TSX:NRI | Q3 2011 results show slow growth | Biotechnology | Download | biotechnology |
10-27-2011 | Medicago Inc. | TSX:MDG | Philip Morris invests another $22.5 million | Biotechnology | Download | biotechnology |
10-27-2011 | PALADIN LABS INC. | TSX:PLB | Preview of Q3 2011 results | Biotechnology | Download | biotechnology |
10-26-2011 | CRH Medical Corp. | TSXV:CRM | Another profitable quarter but growth continues to be slow. Lowering target to $1.00 | Biotechnology | Download | biotechnology |
10-17-2011 | Theratechnologies Inc. | TSX:TH; Q:THER | Q3 F2011 EPS ($0.07). Slow growth of Egrifta® | Biotechnology | Download | biotechnology |
10-03-2011 | | | What Investors Should Look For in a Development-Stage Biotech Company | Biotechnology | Download | biotechnology |
10-03-2011 | PALADIN LABS INC. | TSX:PLB | PLB forgoes offer for Afexa; earns over $5 million on its investment | Biotechnology | Download | biotechnology |
09-28-2011 | Medicago Inc. | TSX:MDG | Lowering price target to $1.00 after $25.0 million equity raise | Biotechnology | Download | biotechnology |
09-23-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | F2011 results reported. Lowering target to $4.50 | Biotechnology | Download | biotechnology |
09-22-2011 | PALADIN LABS INC. | TSX:PLB | ERRATUM: PLB intends to increase bid for Afexa | Biotechnology | Download | biotechnology |
09-20-2011 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q4 F2011 results. Elan decision likely critical to TTH value | Biotechnology | Download | biotechnology |
09-15-2011 | Diagnocure Inc. | TSX:CUR | Updates to CUR model post Q3 F2011 results | Biotechnology | Download | biotechnology |
09-14-2011 | Nuvo Research Inc. | TSX:NRI | Pennsaid® Viscous Solution to be an sNDA filing with FDA | Biotechnology | Download | biotechnology |
08-30-2011 | Diagnocure Inc. | TSX:CUR | Progensa® PCA3 FDA panel meeting delayed. Price target lowered to $1.25 | Biotechnology | Download | biotechnology |
08-30-2011 | Æterna Zentaris.Inc | Q:AEZS; TSX:AEZ | Solorel™ achieves primary endpoint in phase III trial | Biotechnology | Download | biotechnology |
08-30-2011 | PALADIN LABS INC. | TSX:PLB | PLB’s Afexa bid trumped by Valeant | Biotechnology | Download | biotechnology |
08-17-2011 | Diagnocure Inc. | TSX:CUR | Progensa® PCA3 assay approved by Health Canada | Biotechnology | Download | biotechnology |
08-17-2011 | PALADIN LABS INC. | TSX:PLB | PLB to acquire Labopharm for $20.45 million. Increasing rating to Buy, price target to $45.00 | Biotechnology | Download | biotechnology |
08-15-2011 | Medicago Inc. | TSX:MDG | Q2 2011 EPS ($0.03), operational expenses in line with estimates | Biotechnology | Download | biotechnology |
08-12-2011 | PALADIN LABS INC. | TSX:PLB | Q2 2011 results in line with consensus. Price target increased to $43 | Biotechnology | Download | biotechnology |
08-11-2011 | Nuvo Research Inc. | TSX:NRI | Q2 2011 results a little light. Lowering rating to Hold; price target to $0.10 | Biotechnology | Download | biotechnology |
08-11-2011 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q2 2011 results a little lower than expected | Biotechnology | Download | biotechnology |
08-10-2011 | Theratechnologies Inc. | TSX:TH; Q:THER | Upgrading to Hold due to implied return to price target | Biotechnology | Download | biotechnology |
08-10-2011 | PALADIN LABS INC. | TSX:PLB | Nothing to sneeze at – PLB goes hostile on Afexa | Biotechnology | Download | biotechnology |
08-09-2011 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Q2 EPS ($0.13). Next move belongs to Merck. Lowering target to $6.00 | Biotechnology | Download | biotechnology |
08-05-2011 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Q2 2011 operating costs in line. Lowering target to $28.00 due to minor delays in study timing | Biotechnology | Download | biotechnology |
08-05-2011 | PALADIN LABS INC. | TSX:PLB | Preview of Q2 2011 results | Biotechnology | Download | biotechnology |
08-04-2011 | PALADIN LABS INC. | TSX:PLB | Scenario Analysis: Expect positive impact on PLB if PharmaPlan is purchased | Biotechnology | Download | biotechnology |
08-03-2011 | CRH Medical Corp. | TSXV:CRM | Second straight profitable quarter. Price target decreased to $1.25 due to slower than expected top-line growth | Biotechnology | Download | biotechnology |
07-28-2011 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q2 2011 EPS ($0.10). Heavy R&D spend as phase III trial progresses | Biotechnology | Download | biotechnology |
07-27-2011 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Merck steps up to acquire vernakalant IV rights from Astellas | Biotechnology | Download | biotechnology |
07-20-2011 | Nuvo Research Inc. | TSX:NRI | Q2 Pennsaid prescriptions grew as expected | Biotechnology | Download | biotechnology |
07-18-2011 | PALADIN LABS INC. | TSX:PLB | PLB acquires 14.94% of Afexa | Biotechnology | Download | biotechnology |
07-07-2011 | Theratechnologies Inc. | TSX:TH; Q:THER | Q2 F2011 EPS ($0.10). Egrifta sales start slowly | Biotechnology | Download | biotechnology |
07-06-2011 | Canadian Healthcare | | Navigating the Canadian Biotech Space | Biotechnology | Download | biotechnology |
07-06-2011 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Encouraging but not overwhelming interim data from phase II lung cancer trial | Biotechnology | Download | biotechnology |
06-30-2011 | Nuvo Research Inc. | TSX:NRI | Positive Pennsaid viscous solution phase II results | Biotechnology | Download | biotechnology |
06-30-2011 | Medicago Inc. | TSX:MDG | Encouraging results from H5N1 (pandemic flu) phase II study | Biotechnology | Download | biotechnology |
06-29-2011 | Diagnocure Inc. | TSX:CUR | CUR licences Previstage and sells lab to Signal Genetics for US$13.3 million. Raising price target to $1.50 | Biotechnology | Download | biotechnology |
06-15-2011 | Theratechnologies Inc. | TSX:TH | Update on TH. Price target increased to $4.50 but Sell rating maintained | Biotechnology | Download | biotechnology |
06-09-2011 | PALADIN LABS INC. | TSX:PLB | PLB keeping investors alert by investing in drowsiness | Biotechnology | Download | biotechnology |
06-08-2011 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Interim data from phase II lung cancer study highly encouraging | Biotechnology | Download | biotechnology |
06-08-2011 | Medicago Inc. | TSX:MDG | Positive results for H1N1 (seasonal flu) phase I study | Biotechnology | Download | biotechnology |
06-07-2011 | Diagnocure Inc. | TSX:CUR | Q2 F2011 EPS ($0.04). Lowering target to $1.00 | Biotechnology | Download | biotechnology |
06-06-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | ASCO data supports optimism around CYT387 | Biotechnology | Download | biotechnology |
05-31-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | North American nimotuzumab program curtailed | Biotechnology | Download | biotechnology |
05-30-2011 | Medicago Inc. | TSX:MDG | Q1 2011 EPS ($0.04) as expected. Awaiting H5N1 phase II results | Biotechnology | Download | biotechnology |
05-27-2011 | Nuvo Research Inc. | TSX:NRI | Q1 results. Pennsaid reimbursement could have positive impact in H2. Lowering target to $0.15 | Biotechnology | Download | biotechnology |
05-27-2011 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Evaluation of risks with perifosine phase III colorectal trial | Biotechnology | Download | biotechnology |
05-26-2011 | PALADIN LABS INC. | TSX:PLB | Share buyback likely to favourably impact share price | Biotechnology | Download | biotechnology |
05-26-2011 | PALADIN LABS INC. | TSX:PLB | Q1 2011 EBITDA $17.3 million; expect profit-taking on these results. Lowering target to $41.00 | Biotechnology | Download | biotechnology |
05-24-2011 | PALADIN LABS INC. | TSX:PLB | Q1 preview; expect another strong quarter. Raising price target to $42.00 | Biotechnology | Download | biotechnology |
05-19-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | ASCO abstract previews limited data for upcoming conference | Biotechnology | Download | biotechnology |
05-12-2011 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q1 2011 EPS ($0.06); Reolysin studies progressing | Biotechnology | Download | biotechnology |
05-12-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Q3 F2011 EPS ($0.06). Increasing price target to $5.00 | Biotechnology | Download | biotechnology |
05-12-2011 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q3 F2011 EPS ($0.13). No news on ELND005. Early stage compounds progressing slowly | Biotechnology | Download | biotechnology |
05-11-2011 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Prepping Reolysin for market | Biotechnology | Download | biotechnology |
05-10-2011 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Q1 2011 EPS ($0.31). Modifications to SATURN trial to keep it relevant | Biotechnology | Download | biotechnology |
05-04-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Latest activity in the JAK inhibitor world | Biotechnology | Download | biotechnology |
04-28-2011 | CRH Medical Corp. | TSXV:CRM | CRM announces preliminary profitable Q1. Poised for growth. Lowering target to $1.75 | Biotechnology | Download | biotechnology |
04-26-2011 | CRH Medical Corp. | NYSE MKT:CRHM, TSX:CRH | 2010 EPS ($0.03). Company expected to reach profitability in the near-term | Biotechnology | Download | biotechnology |
04-21-2011 | Medicago Inc. | TSX:MDG | Tobacco and vaccines – “There’s an App for that”™ | Biotechnology | Download | biotechnology |
04-18-2011 | Nuvo Research Inc. | TSX:NRI | Easing the pain: Acquisition of ZARS Pharma | Biotechnology | Download | biotechnology |
04-18-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Latest anemia data appear promising | Biotechnology | Download | biotechnology |
04-13-2011 | Theratechnologies Inc. | TSX:TH | Q1 F2011 EPS ($0.10). Egrifta™ sales to be reported in fiscal Q2 | Biotechnology | Download | biotechnology |
04-04-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Update on myelofibrosis from principal investigator in CYT387 trial | Biotechnology | Download | biotechnology |
03-23-2011 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | 2010 EPS ($0.31) better than expected. Raising target to $2.50 | Biotechnology | Download | biotechnology |
03-17-2011 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | 2010 EPS ($0.32); expect newsworthy 2011 | Biotechnology | Download | biotechnology |
03-15-2011 | Diagnocure Inc. | TSX:CUR | Q1 F2011 results in line. Upgrading to Hold based on implied return | Biotechnology | Download | biotechnology |
03-14-2011 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | 2010 EPS ($1.79); better than expected. Increasing target to $30.00 | Biotechnology | Download | biotechnology |
03-14-2011 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Clinical development slowed. Price target lowered to $7.00 | Biotechnology | Download | biotechnology |
03-14-2011 | Theratechnologies Inc. | TSX:TH | Cancellation of equity offering results in price target increase to $4.00 | Biotechnology | Download | biotechnology |
03-01-2011 | Nuvo Research Inc. | TSX:NRI | Q4 2011 results show slow growth. 2012 off to a good start | Biotechnology | Download | biotechnology |
02-28-2011 | PALADIN LABS INC. | TSX:PLB | Resuming coverage: Price target increased to $37.00 | Biotechnology | Download | biotechnology |
02-25-2011 | Nuvo Research Inc. | TSX:NRI | 2010 EPS ($0.02). Pennsaid sales affected by lack of reimbursement. Target lowered to $0.30 | Biotechnology | Download | biotechnology |
02-23-2011 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | EU regulators recommend additional contraindication for Brinavess™. Price target lowered to $7.50 | Biotechnology | Download | biotechnology |
02-23-2011 | Theratechnologies Inc. | TSX:TH | TH files secondary offering. Second indication for tesamorelin to be COPD muscle wasting. Target lowered to $3.50 | Biotechnology | Download | biotechnology |
02-10-2011 | Theratechnologies Inc. | TSX:TH | F2010 EPS $0.15; lowering price target to $4.50 | Biotechnology | Download | biotechnology |
02-10-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Q2 F2011 EPS ($0.10); an eventful year ahead | Biotechnology | Download | biotechnology |
02-09-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Upgrading from Hold to Buy | Biotechnology | Download | biotechnology |
02-08-2011 | Nuvo Research Inc. | TSX:NRI | Initiating coverage: Buy, Speculative Risk Rating, $0.35 price target | Biotechnology | Download | biotechnology |
02-08-2011 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q2 F2011 EPS $1.05 due to recognition of Elan payments | Biotechnology | Download | biotechnology |
02-03-2011 | Diagnocure Inc. | TSX:CUR | F2010 results as expected | Biotechnology | Download | biotechnology |
02-02-2011 | PALADIN LABS INC. | TSX:PLB | A little pain relief: Acquisition of Tempra, divestiture of ISA shares | Biotechnology | Download | biotechnology |
01-20-2011 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | With modified Elan agreement, price target lowered to $2.50 | Biotechnology | Download | biotechnology |
01-19-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Nimotuzumab fails to improve PFS in phase II gastric cancer study | Biotechnology | Download | biotechnology |
01-18-2011 | PALADIN LABS INC. | TSX:PLB | Raising price target to $35.00 due to rolling forward estimates | Biotechnology | Download | biotechnology |
01-05-2011 | Canadian Healthcare | | Navigating the Canadian Biotech Space | Biotechnology | Download | biotechnology |
01-04-2011 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Resuming coverage after equity raise. Target upped to $3.50 | Biotechnology | Download | biotechnology |
12-23-2010 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Raising price target to $8.00 due to rolling forward valuation | Biotechnology | Download | biotechnology |
12-23-2010 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Increasing price target to $8.50 due to rolling forward valuation | Biotechnology | Download | biotechnology |
12-23-2010 | CRH Medical Corp. | TSXV:CRM | Raising price target to $2.00 due to rolling forward valuation | Biotechnology | Download | biotechnology |
12-22-2010 | Theratechnologies Inc. | TSX:TH | Tweaking model to reflect milestone received in F2010 | Biotechnology | Download | biotechnology |
12-20-2010 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Solorel™ gets green light for continued testing | Biotechnology | Download | biotechnology |
12-16-2010 | PALADIN LABS INC. | TSX:PLB | The “Bank of Paladin” makes another investment | Biotechnology | Download | biotechnology |
12-09-2010 | Theratechnologies Inc. | TSX:TH | Egrifta licensing deal helps set the stage for the future | Biotechnology | Download | biotechnology |
12-09-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Downgrading to Hold, price target lowered to $3.50 | Biotechnology | Download | biotechnology |
11-25-2010 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | CYT387 – Preview of ASH conference | Biotechnology | Download | biotechnology |
11-18-2010 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Resuming coverage post capital raise. Raising price target to $6.00 | Biotechnology | Download | biotechnology |
11-18-2010 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | AEZS-108 phase II endometrial cancer data warrants further study | Biotechnology | Download | biotechnology |
11-18-2010 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Expansion of CYT387 phase I/II trial to determine appropriate dosing | Biotechnology | Download | biotechnology |
11-15-2010 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Q3 2010 EPS $0.37. Holding for an FDA decision on ACT 5 | Biotechnology | Download | biotechnology |
11-11-2010 | Theratechnologies Inc. | TSX:TH | A day to remember: FDA approves Egrifta™. Lowering rating to Sell, price target to $4.50 | Biotechnology | Download | biotechnology |
11-11-2010 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Q1 F2011 EPS ($0.09); in line with our estimate | Biotechnology | Download | biotechnology |
11-11-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q1 F2011 EPS ($0.19); lowering target to $4.50 | Biotechnology | Download | biotechnology |
11-10-2010 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q3 2010 EPS ($0.12). No surprises | Biotechnology | Download | biotechnology |
11-04-2010 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Q3 2010 EPS ($1.07); includes $4.0 million restructuring charge | Biotechnology | Download | biotechnology |
11-04-2010 | PALADIN LABS INC. | TSX:PLB | Q3 2010 results: Strong EBITDA on lower than expected costs | Biotechnology | Download | biotechnology |
11-02-2010 | CRH Medical Corp. | TSXV:CRM | CRM to focus exclusively on direct sales to gastroenterologists | Biotechnology | Download | biotechnology |
10-29-2010 | CRH Medical Corp. | TSXV:CRM | Q3 2010 EPS (0.005); on the verge of break-even | Biotechnology | Download | biotechnology |
10-28-2010 | PALADIN LABS INC. | TSX:PLB | Preview of Q3 results | Biotechnology | Download | biotechnology |
10-25-2010 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | A shocking event. Advise caution in advance of FDA feedback | Biotechnology | Download | biotechnology |
10-19-2010 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | OGXI raises $50 million in public financing. Target price lowered to $25.00 | Biotechnology | Download | biotechnology |
10-14-2010 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Possibility of a Reolysin partnering deal sooner than later. Increasing price target to $5.50 | Biotechnology | Download | biotechnology |
10-14-2010 | PALADIN LABS INC. | TSX:PLB | PLB adds pain development-stage products to pipeline | Biotechnology | Download | biotechnology |
10-13-2010 | Theratechnologies Inc. | TSX:TH | Q3 F2010 EPS (0.05); FDA decision expected near-term | Biotechnology | Download | biotechnology |
09-30-2010 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | SYNERGY study starts. OGXI well positioned for the future | Biotechnology | Download | biotechnology |
09-28-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | F2010 EPS ($0.83); in line with estimate | Biotechnology | Download | biotechnology |
09-24-2010 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | F2010 EPS ($0.33); affected by intangible asset write-offs | | Download | |
09-22-2010 | Diagnocure Inc. | TSX:CUR | Progensa™ submitted for FDA approval | Biotechnology | Download | biotechnology |
09-17-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | TT-223 fails in phase II. Lowering price target to $6.00 | Biotechnology | Download | biotechnology |
09-14-2010 | Diagnocure Inc. | TSX:CUR | Q3 results review. Downgrading to Sell | Biotechnology | Download | biotechnology |
09-09-2010 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Update on JAK2 inhibitors – what CYT387 is up against. Increasing price target to $2.25 due to rolling forward estimates | Biotechnology | Download | biotechnology |
09-09-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Potential Alzheimer’s drug competitors and possible TTH partners | Biotechnology | Download | biotechnology |
09-07-2010 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Updated view post Brinavess™ approval | Biotechnology | Download | biotechnology |
08-16-2010 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Update to CRME financials. No change to our view | Biotechnology | Download | biotechnology |
08-13-2010 | CRH Medical Corp. | TSXV:CRM | Q2 results weaker than expected. Lowering target to $1.75 | Biotechnology | Download | biotechnology |
08-12-2010 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q2 2010 EPS ($0.06). Price target increased to $1.50 | Biotechnology | Download | biotechnology |
08-11-2010 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Phase III oral vernakalant program delayed | Biotechnology | Download | biotechnology |
08-10-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | No new news post the ELND005 conference call. Reducing price target to $4.50 | Biotechnology | Download | biotechnology |
08-09-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | ELND005 will be taken to phase III | Biotechnology | Download | biotechnology |
08-05-2010 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Q2 2010 EPS $0.02. Focus shifting to OGX-427 | Biotechnology | Download | biotechnology |
08-05-2010 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | CYT387 phase I dose escalation complete. Phase II expanded | Biotechnology | Download | biotechnology |
08-05-2010 | PALADIN LABS INC. | TSX:PLB | Q2 results impress. Upgrading to Buy, price target to $31.00 | Biotechnology | Download | biotechnology |
08-03-2010 | Diagnocure Inc. | TSX:CUR | New York State lab permit likely more important for future tests than Previstage | Biotechnology | Download | biotechnology |
07-29-2010 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q2 2010 EPS ($0.07); in line with estimates | Biotechnology | Download | biotechnology |
07-29-2010 | PALADIN LABS INC. | TSX:PLB | Preview of upcoming Q2 results | Biotechnology | Download | biotechnology |
07-08-2010 | Theratechnologies Inc. | TSX:TH | Q2 F2010 EPS (0.08). Waiting for FDA decision | Biotechnology | Download | biotechnology |
07-05-2010 | Canadian Healthcare | | Navigating the Canadian Biotech Space | Biotechnology | Download | biotechnology |
06-25-2010 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Positive CHMP opinion received for Brinavess™ | Biotechnology | Download | biotechnology |
06-24-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | TTH fairly valued if you assume ELND005 will fail; otherwise, cheap. Upgrading to Buy | Biotechnology | Download | biotechnology |
06-23-2010 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Minor model revisions due to $3 million tax recovery | Biotechnology | Download | biotechnology |
06-21-2010 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | OGX-011 phase III starts on time. Reiterate Buy rating | Biotechnology | Download | biotechnology |
06-16-2010 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Another round of financing; if warrants are exercised it may be enough. Raising rating to Hold | Biotechnology | Download | biotechnology |
06-15-2010 | YM Biosciences Inc. | TSX:YM; AMEX:YMI | Initiating coverage of YM: Looking out for nimo | Biotechnology | Download | biotechnology |
06-10-2010 | Diagnocure Inc. | TSX:CUR | Q2 F2010 EPS ($0.05); minimal revenue growth but expenses under control | Biotechnology | Download | biotechnology |
06-08-2010 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Updated Reolysin phase I/II head & neck cancer data support previous findings | Biotechnology | Download | biotechnology |
05-28-2010 | Theratechnologies Inc. | TSX:TH | Positive panel meeting bodes well for final FDA decision. Upgrading to Hold | Biotechnology | Download | biotechnology |
05-25-2010 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Enrollment opened in Reolysin phase III head and neck cancer trial | Biotechnology | Download | biotechnology |
05-25-2010 | Theratechnologies Inc. | TSX:TH | Tesamorelin briefing package released by FDA | Biotechnology | Download | biotechnology |
05-21-2010 | | | ASCO 2010 – Abstracts from AEZS, ONC and OGXI | Biotechnology | Download | biotechnology |
05-20-2010 | Theratechnologies Inc. | TSX:TH | Expectations for tesamorelin (Egrifta™) briefing package | Biotechnology | Download | biotechnology |
05-18-2010 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Encouraging results from early-stage trial on Reolysin plus radiotherapy | Biotechnology | Download | biotechnology |
05-17-2010 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | AVRO data look good. Increasing price target to $7.00 | Biotechnology | Download | biotechnology |
05-13-2010 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q1 2010 EPS ($0.09). Raising target to $1.25 | Biotechnology | Download | biotechnology |
05-12-2010 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q1 2010 EPS ($0.07) | Biotechnology | Download | biotechnology |
05-11-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q3 F2010 EPS ($0.13). Waiting for ELND005 phase II results | Biotechnology | Download | biotechnology |
05-06-2010 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Q1 2010 EPS ($0.48). OGX-011 development on schedule | Biotechnology | Download | biotechnology |
05-06-2010 | PALADIN LABS INC. | TSX:PLB | A solid start to the year. Increasing price target to $28.00 | Biotechnology | Download | biotechnology |
04-29-2010 | CRH Medical Corp. | TSXV:CRM | Q1 2010 EPS ($0.01). No surprises | | Download | |
04-28-2010 | CRH Medical Corp. | TSXV:CRM | 2009 EPS ($0.05). Product sales growing but center sales stagnant | Biotechnology | Download | biotechnology |
04-16-2010 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | AEZS capitalizes on stock gains to raise $15 million. Raising price target to $1.00 | Biotechnology | Download | biotechnology |
04-15-2010 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | European regulators confirm one phase III multiple myeloma perifosine study sufficient | Biotechnology | Download | biotechnology |
04-13-2010 | | | ASCO 2010 – Presentations on Canadian Company Products | Biotechnology | Download | biotechnology |
04-07-2010 | PALADIN LABS INC. | TSX:PLB | Seasonique® approved; another product in the stable | Biotechnology | Download | biotechnology |
03-30-2010 | Oncogenex Pharmaceuticals Inc. | NASDAQ: OGXI | Initiating coverage of OGXI: Enhancing chemotherapy by targeting clusterin | Biotechnology | Download | biotechnology |
03-30-2010 | Diagnocure Inc. | TSX:CUR | Myriad human gene patents invalidated; highlights risk potential for CUR | Biotechnology | Download | biotechnology |
03-24-2010 | Theratechnologies Inc. | TSX:TH | Q1 F2010 EPS ($0.07); in line with estimates | Biotechnology | Download | biotechnology |
03-24-2010 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | 2009 EPS ($0.43). Benefitting from one-time adjustments | Biotechnology | Download | biotechnology |
03-18-2010 | Diagnocure Inc. | TSX:CUR | Q1 F2010 EPS ($0.09), lower than expected mainly due to restructuring charges | Biotechnology | Download | biotechnology |
03-17-2010 | Theratechnologies Inc. | TSX:TH | Downgrading shares from Buy to Sell due to share price appreciation | Biotechnology | Download | biotechnology |
03-17-2010 | PALADIN LABS INC. | TSX:PLB | Getting to Jo’burg before the World Cup. Price target increased to $23.50 | Biotechnology | Download | biotechnology |
03-09-2010 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | 2009 EPS ($0.33), lower than expected due to R&D spend | Biotechnology | Download | biotechnology |
03-09-2010 | PALADIN LABS INC. | TSX:PLB | Initiating coverage of PLB: The tortoise could win the race | Biotechnology | Download | biotechnology |
03-09-2010 | PALADIN LABS INC. | TSX:PLB | Initiating coverage of PLB: The tortoise could win the race | Biotechnology | Download | biotechnology |
03-03-2010 | CRH Medical Corp. | TSXV:CRM | Downgrading shares to Hold based on share price appreciation | Biotechnology | Download | biotechnology |
03-03-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Licensing and collaboration deal to develop Lilly preclinical diabetes drug | Biotechnology | Download | biotechnology |
02-25-2010 | Theratechnologies Inc. | TSX:TH | FDA Advisory Committee meeting May 27, 2010 | Biotechnology | Download | biotechnology |
02-24-2010 | Canadian Healthcare | | Navigating the Canadian Biotech Space | Biotechnology | Download | biotechnology |
02-17-2010 | CRH Medical Corp. | TSXV:CRM | China deal adds to distribution network | Biotechnology | Download | biotechnology |
02-16-2010 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | A step in the right direction. UK regulators approve start of phase III Reolysin study | Biotechnology | Download | biotechnology |
02-16-2010 | Diagnocure Inc. | TSX:CUR | CUR restructuring aimed at extending cash runway | Biotechnology | Download | biotechnology |
02-11-2010 | Theratechnologies Inc. | TSX:TH | F2009 EPS ($0.25); in line with estimates | Biotechnology | Download | biotechnology |
02-11-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q2 F2010 results mostly in line with estimates | Biotechnology | Download | biotechnology |
02-03-2010 | Theratechnologies Inc. | TSX:TH | EU deal for tesamorelin. Price target upped to $6.00 | Biotechnology | Download | biotechnology |
02-02-2010 | Theratechnologies Inc. | TSX:TH | How to obtain Egrifta™ in the U.S | Biotechnology | Download | biotechnology |
02-02-2010 | Diagnocure Inc. | TSX:CUR | Update of financial model post year-end results. No change to our view | Biotechnology | Download | biotechnology |
02-01-2010 | Theratechnologies Inc. | TSX:TH | Update on TH. Lowering price target from $5.50 to $5.00 but reiterate Buy rating | Biotechnology | Download | biotechnology |
01-25-2010 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Phase II TT-223 monotherapy data encouraging, but mixed. Target lowered to $9.00 (from $9.50) | Biotechnology | Download | biotechnology |
01-15-2010 | Diagnocure Inc. | TSX:CUR | F2009 results as expected | Biotechnology | Download | biotechnology |
01-05-2010 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Highly encouraging perifosine colon cancer phase II data | Biotechnology | Download | biotechnology |
12-17-2009 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Vernakalant IV comparator trial meets primary endpoint | Biotechnology | Download | biotechnology |
12-15-2009 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | ELND005 safety questioned. Lowering rating to Hold and target to $9.50 | Biotechnology | Download | biotechnology |
12-14-2009 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Upgrading to Buy Rating. Re-instituting research coverage | Biotechnology | Download | biotechnology |
12-07-2009 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Cetrorelix development dealt a likely fatal blow. Downgrading AEZS to Sell | Biotechnology | Download | biotechnology |
12-02-2009 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Vernakalant IV comparator trial results expected soon | Biotechnology | Download | biotechnology |
12-01-2009 | Diagnocure Inc. | TSX:CUR | Molecular Diagnostics – Aiming for better cancer predictability | Biotechnology | Download | biotechnology |
12-01-2009 | Diagnocure Inc. | TSX:CUR | Initiating coverage of CUR: Aiming for better cancer predictability | Biotechnology | Download | biotechnology |
12-01-2009 | CRH Medical Corp. | TSXV:CRM | Q3 2009 EPS (US$0.01), in line with our estimates | Biotechnology | Download | biotechnology |
11-17-2009 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Scenario analysis on second set of cetrorelix BPH phase III data | Biotechnology | Download | biotechnology |
11-11-2009 | Æterna Zentaris Inc. | Q:AEZS; TSX:AEZ | Q3 2009 EPS ($0.19), in line with our estimate | Biotechnology | Download | biotechnology |
11-10-2009 | Transition Therapeutics Inc. | TSX:TTH, Q:TTHI | Q1 F2010 EPS ($0.24). Waiting for decision on phase III Alzheimer’s program | Biotechnology | Download | biotechnology |
11-09-2009 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Q3 2009 EPS ($ 0.01). Higher than expected R&D | Biotechnology | Download | biotechnology |
11-05-2009 | Oncolytics Biotech Inc. | TSX:ONC; Q:ONCY | Q3 2009 EPS ($ 0.05); better than expected due to lower R&D | Biotechnology | Download | biotechnology |
11-05-2009 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Raising target and upgrading to Hold based on implied return and share consolidation | | Download | |
11-05-2009 | Theratechnologies Inc. | TSX:TH | Tesamorelin to be reviewed by FDA Advisory Committee | Biotechnology | Download | biotechnology |
09-28-2009 | | | Initiating Coverage of Six Biotech Companies | Biotechnology | Download | biotechnology |
03-17-2009 | Cardiome Pharma Corp. | NASDAQ:CRME; TSX:COM | Increasing price target to US$6.50 due to model adjustments related to conversion to US GAAP | Biotechnology | Download | biotechnology |
Recent Comments